Owens & Minor (OMI) 10-K 20 Feb 24 2023 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2023	Jan. 31, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-9810
Entity Registrant Name	OWENS & MINOR, INC
Entity Incorporation, State or Country Code	VA
Entity Tax Identification Number	54-1701843
Entity Address, Address Line One	9120 Lockwood Boulevard
Entity Address, City or Town	Mechanicsville
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	23116
City Area Code	804
Local Phone Number	723-7000
Title of 12(b) Security	Common Stock, $2 par value
Trading Symbol	OMI
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller reporting company	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 1,423,793,358
Entity Common Stock, Shares Outstanding		76,596,696
Documents Incorporated by Reference	The proxy statement for the annual meeting of shareholders to be held on May 9, 2024, is incorporated by reference for Item 5 of Part II and Part III.
Auditor Name	KPMG, LLP
Auditor Location	Richmond, VA
Auditor Firm ID	185
Entity Central Index Key	0000075252
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue	$ 10,333,967	$ 9,955,475	$ 9,785,315
Cost of goods sold	8,208,806	8,129,124	8,272,086
Gross margin	2,125,161	1,826,351	1,513,229
Distribution, selling and administrative expenses	1,813,559	1,554,821	1,077,064
Acquisition-related charges and intangible amortization	101,037	126,972	42,774
Exit and realignment charges	99,127	6,897	31,109
Other operating expense (income), net	6,930	(5,252)	(6,191)
Operating income	104,508	142,913	368,473
Interest expense, net	157,915	128,891	48,090
(Gain) loss on extinguishment of debt	(3,518)	0	40,433
Other expense, net	4,837	3,131	3,196
(Loss) income before income taxes	(54,726)	10,891	276,754
Income tax (benefit) provision	(13,425)	(11,498)	55,165
Net (loss) income	$ (41,301)	$ 22,389	$ 221,589
Net (loss) income per common share:
Basic (in dollars per share)	$ (0.54)	$ 0.30	$ 3.05
Diluted (in dollars per share)	$ (0.54)	$ 0.29	$ 2.94

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (41,301)	$ 22,389	$ 221,589
Other comprehensive income (loss) net of tax:
Currency translation adjustments	7,141	(14,101)	(25,976)
Change in unrecognized net periodic pension costs	2,086	7,396	3,850
Change in gains and losses on derivative instruments	(5,190)	11,441	20,044
Total other comprehensive income (loss), net of tax	4,037	4,736	(2,082)
Comprehensive (loss) income	$ (37,264)	$ 27,125	$ 219,507

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 243,037	$ 69,467
Accounts receivable, net	598,257	763,497
Merchandise inventories	1,110,606	1,333,585
Other current assets	150,890	128,636
Total current assets	2,102,790	2,295,185
Property and equipment, net	543,972	578,269
Operating lease assets	296,533	280,665
Goodwill	1,638,846	1,636,705
Intangible assets, net	361,835	445,042
Other assets, net	149,346	150,417
Total assets	5,093,322	5,386,283
Current liabilities
Accounts payable	1,171,882	1,147,414
Accrued payroll and related liabilities	116,398	93,296
Current portion of long-term debt	206,904	17,906
Other current liabilities	396,701	307,850
Total current liabilities	1,891,885	1,566,466
Long-term debt, excluding current portion	1,890,598	2,482,968
Operating lease liabilities, excluding current portion	222,429	215,469
Deferred income taxes	41,652	60,833
Other liabilities	122,592	114,943
Total liabilities	4,169,156	4,440,679
Commitments and contingencies
Equity
Common stock, par value $2 per share; authorized - 200,000 shares; issued and outstanding - 76,546 shares and 76,279 shares as of December 31, 2023 and December 31, 2022	153,092	152,557
Paid-in capital	434,185	418,894
Retained earnings	368,707	410,008
Accumulated other comprehensive loss	(31,818)	(35,855)
Total equity	924,166	945,604
Total liabilities and equity	$ 5,093,322	$ 5,386,283

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 2	$ 2
Common stock, authorized (shares)	200,000	200,000
Common stock, issued (shares)	76,546	76,279
Commons stock, outstanding (shares)	76,546	76,279

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating activities:
Net (loss) income	$ (41,301)	$ 22,389	$ 221,589
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	287,377	228,667	90,621
Share-based compensation expense	23,218	20,993	25,016
(Gain) loss on extinguishment of debt	(3,518)	0	40,433
Deferred income tax benefit	(23,648)	(26,361)	(29,736)
(Benefit) provision for losses on accounts receivable	(1,414)	3,315	21,158
Changes in operating lease right-of-use assets and lease liabilities	(47)	353	1,463
Gain on sale and dispositions of property and equipment	(34,882)	(26,260)	0
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	166,581	1,101	(2,201)
Merchandise inventories	224,338	166,559	(263,439)
Accounts payable	30,997	13,652	3,548
Net change in other assets and liabilities	100,370	(91,544)	692
Other, net	12,639	12,142	15,033
Cash provided by operating activities	740,710	325,006	124,177
Investing activities:
Acquisition, net of cash acquired	0	(1,684,607)	0
Additions to property and equipment	(190,870)	(158,090)	(40,985)
Additions to computer software	(17,022)	(8,492)	(8,705)
Proceeds from sale of property and equipment	71,574	48,383	0
Other, net	(936)	(1,670)	(3,940)
Cash used for investing activities	(137,254)	(1,804,476)	(53,630)
Financing activities:
Borrowings under amended Receivables Financing Agreement	476,000	1,022,300	0
Repayments under amended Receivables Financing Agreement	(572,000)	(1,156,300)	0
Repayments of debt	(320,693)	(4,500)	(553,140)
Proceeds from issuance of debt	0	1,691,000	574,900
Borrowings (repayments) under revolving credit facility, net and Receivables Financing Agreement	0	30,000	(103,200)
Financing costs paid	0	(42,602)	(13,912)
Cash dividends paid	0	0	(731)
Payment for termination of interest rate swaps	0	0	(15,434)
Other, net	(637)	(42,793)	(17,961)
Cash (used for) provided by financing activities	(417,330)	1,497,105	(129,478)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	613	(3,485)	(3,540)
Net increase in cash, cash equivalents and restricted cash	186,739	14,150	(62,471)
Cash, cash equivalents and restricted cash at beginning of period	86,185	72,035	134,506
Cash, cash equivalents and restricted cash at end of period	272,924	86,185	72,035
Supplemental disclosure of cash flow information:
Income taxes (received) paid, net	(6,283)	33,973	99,400
Interest paid	153,247	107,022	38,717
Noncash investing activity:
Unpaid purchases of property and equipment and computer software at end of period	$ 77,279	$ 67,852	$ 0

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total
Beginning balance (in shares) at Dec. 31, 2020	73,472
Beginning balance at Dec. 31, 2020	$ 146,944	$ 436,597	$ 167,022	$ (38,509)	$ 712,054
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income			221,589		221,589
Other comprehensive income				(2,082)	(2,082)
Dividends declared			(992)		(992)
Share-based compensation expense, exercises and other (in shares)	1,961
Share-based compensation expense, exercises and other	$ 3,921	4,011			7,932
Ending balance (in shares) at Dec. 31, 2021	75,433
Ending balance at Dec. 31, 2021	$ 150,865	440,608	387,619	(40,591)	938,501
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income			22,389		22,389
Other comprehensive income				4,736	4,736
Share-based compensation expense, exercises and other (in shares)	846
Share-based compensation expense, exercises and other	$ 1,692	(21,714)			$ (20,022)
Ending balance (in shares) at Dec. 31, 2022	76,279				76,279
Ending balance at Dec. 31, 2022	$ 152,557	418,894	410,008	(35,855)	$ 945,604
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income			(41,301)		(41,301)
Other comprehensive income				4,037	4,037
Share-based compensation expense, exercises and other (in shares)	267
Share-based compensation expense, exercises and other	$ 535	15,291			$ 15,826
Ending balance (in shares) at Dec. 31, 2023	76,546				76,546
Ending balance at Dec. 31, 2023	$ 153,092	$ 434,185	$ 368,707	$ (31,818)	$ 924,166

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)	12 Months Ended
	Dec. 31, 2021 $ / shares
Statement of Stockholders' Equity [Abstract]
Common stock, par value (in usd per share)	$ 2
Dividends declared, per share (in usd per share)	$ 0.01

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	OWENS & MINOR, INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (in thousands, except per share data, unless otherwise indicated) Note 1—Summary of Significant Accounting Policies Owens & Minor, Inc. and subsidiaries (we, us, our or the Company), a Fortune 500 company headquartered in Richmond, Virginia, is a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services to deliver significant and sustained value across the breadth of the industry – from acute care to patients in their home. Our teammates serve healthcare industry customers in approximately 80 countries by producing quality products and helping to reduce total costs across the healthcare supply chain by optimizing point-of care performance, freeing up capital and clinical resources and managing contracts to optimize financial performance. Basis of Presentation and Consolidation. We report our business under two distinct segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment includes our United States (U.S.) distribution division (Medical Distribution), including outsourced logistics and value-added services, and Global Products division which manufactures and sources medical surgical products through our production and kitting operations. The Patient Direct segment includes our home healthcare divisions (Byram and Apria). Reclassifications. Use of Estimates. Cash, Cash Equivalents and Restricted Cash. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of those same amounts presented in the accompanying consolidated statements of cash flows. ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 December 31, 2022 Cash and cash equivalents ​ $ 243,037 ​ $ 69,467 Restricted cash included in Other current assets ​ 29,887 ​ — Restricted cash included in Other assets, net ​ ​ — ​ ​ 16,718 Total cash, cash equivalents, and restricted cash ​ $ 272,924 ​ $ 86,185 ​ Book overdrafts represent the amount of outstanding checks issued in excess of related bank balances and are included in accounts payable in our consolidated balance sheets, as they are similar to trade payables and are not subject to finance charges or interest. Changes in book overdrafts are classified as operating activities in our consolidated statements of cash flows. Accounts Receivable, Net. Due to the nature of our industry and the reimbursement environment in which we operate in the Patient Direct segment, certain estimates are required to record total net revenues and accounts receivable at their net realizable values, including estimating variable consideration. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements, contractual terms, and the uncertainty of reimbursement amounts for certain services may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. We maintain valuation allowances based upon the expected collectability of accounts receivable. Our allowances include specific amounts for accounts that are likely to be uncollectible, such as customer bankruptcies and disputed amounts and general allowances for accounts that may become uncollectible. Allowances are estimated based on a number of factors, including industry trends, current economic conditions, creditworthiness of customers, age of the receivables, changes in customer payment patterns, and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Allowances for losses on accounts receivable of $7.9 million and $9.1 million have been applied as reductions of accounts receivable at December 31, 2023 and 2022. On March 14, 2023, we entered into the RPA, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed $200 million are sold, on a limited-recourse basis, to the Purchaser in exchange for cash. As of December 31, 2023, there were a total of $124 million of uncollected accounts receivable that had been sold or removed from our consolidated balance sheet. We account for these transactions as sales with the sold receivables removed from our consolidated balance sheets. Under the RPA, we provide certain servicing and collection actions on behalf of the Purchaser; however, we do not maintain any beneficial interest in the accounts receivable sold. The RPA is separate and distinct from the accounts receivable securitization program (the Receivables Financing Agreement). Proceeds from the sales of accounts receivable are recorded as an increase to cash and cash equivalents and a reduction to accounts receivable, net of allowances in the consolidated balance sheets. Cash received from the sales of accounts receivable, net of payments made to the Purchaser, is reflected in the change in accounts receivable within cash provided by operating activities in the consolidated statements of cash flows. Total accounts receivable sold under the RPA and net cash proceeds were $1.4 billion during the year ended December 31, 2023. We collected $1.3 billion of the sold accounts receivable for the year ended December 31, 2023. The losses on sales of accounts receivable are recorded in other operating expense (income), net in the consolidated statements of operations and were $10.6 million for the year ended December 31, 2023. Merchandise Inventories. We periodically evaluate whether inventory valuation allowance adjustments are required, which includes consideration of recent sales trends. In our evaluation, we review for expired or obsolete inventory and slow-moving inventory. We write down inventories which are considered excess and obsolete as a result of these assessments. Shifts in market trends and conditions, as well as changes in customer preferences and behavior could affect the value of our inventories. Property and Equipment, net. three five one Leases. one nine one three Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We elected the practical expedient to not separate lease and non-lease components for our leases. Operating lease assets and liabilities are recognized at commencement date based on the present value of unpaid lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments. We use the implicit rate when readily determinable. The right-of-use assets also include adjustments for any lease payments made and lease incentives received. Goodwill. We evaluate goodwill for impairment annually, as of October 1, and if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. As of October 1, 2023, due to changes in our long-term financial plan assumptions, we elected to bypass the qualitative test and performed a quantitative goodwill impairment test for all reporting units with goodwill. We determine the estimated fair value of our reporting units by using an equally weighted combination of the income-based approach and the market-based approach. The income-based approach is dependent upon several significant assumptions and estimates regarding future period cash flows, including assumptions with respect to future sales growth and a terminal growth rate. In addition, a weighted average cost of capital (WACC) is used to discount future estimated cash flows to their present values. The WACC is based on externally observable data considering market participants’ cost of equity and debt, optimal capital structure and interest rates, as well as the risk and uncertainty with respect to the reporting unit and internally developed financial projections. Under the market-based approach, significant estimates and assumptions also include the selection of appropriate guideline public companies whose stock is actively traded in public markets and the determination of appropriate valuation multiples to apply to the reporting unit. Although we believe our assumptions and estimates are reasonable and appropriate, any significant adverse changes in one or a combination of key assumptions, including, but not limited to, a failure to meet our business plans or expected earnings and cash flows, unanticipated events and circumstances such as changes in assumptions about the duration and magnitude of increased supply chain expense, commodities costs or inflationary pressures and our planned efforts to mitigate such impacts, disruptions in the supply chain, estimated demand and selling prices for PPE or other products, an increase in the discount rate, a decrease in the terminal growth rate, increases in tax rates (including potential tax reform) or a significant change in industry or economic trends, may affect the accuracy or validity of such estimates and may result in goodwill impairment. We may be required to record a material charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill is determined, which could adversely affect our results of operations. No impairment of goodwill was recorded for the years ended December 31, 2023, 2022, and 2021. Intangible Assets, net. one Computer Software. three Long-Lived Assets. Self-Insurance Liabilities. automobile liability claims are estimated using historical claims data and loss development factors. If the underlying facts and circumstances of existing claims change or historical trends are not indicative of future trends, then we may be required to adjust the liability and related expense accordingly. Self-insurance liabilities are included in other current liabilities and other liabilities in the consolidated balance sheets and were $26.0 million and $25.6 million in total at December 31, 2023 and 2022. Revenue Recognition. In our Products & Healthcare Services segment, under most of our distribution and product sales arrangements, our performance obligations are limited to delivery of products to a customer upon receipt of a purchase order. For these arrangements, we recognize revenue at the point in time when shipment is completed, as control passes to the customer upon product receipt. Our contracts sometime allow for forms of variable consideration including rebates, discounts, performance guarantees, and implicit price concessions. We estimate the amount of consideration to which we will be entitled in exchange for transferring the product or service to the customer under the expected value method as part of determining the sales transaction price using contractual terms, historical experience, and other operating trends. The amounts accrued for rebates due to customers, which are recorded in accounts receivable, net, were $81.3 million and $86.9 million at December 31, 2023 and 2022. In most cases, we record revenue gross, as we are the primary obligor. When we act as an agent in a sales arrangement and do not bear a significant portion of inventory risks, primarily for our outsourced logistics business, we record revenue net of product cost. Sales taxes collected from customers and remitted to governmental authorities are excluded from revenues. Within our Patient Direct segment, revenues are recognized under fee-for-service arrangements for equipment we rent to patients and sales of equipment, supplies and other items we sell to patients. Revenue that is generated from equipment that we rent to patients is primarily recognized over the noncancelable rental period, typically one month, and commences on delivery of the equipment to the patients. Revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. Rental revenue, less estimated adjustments, is recognized as earned on a straight-line basis over the noncancellable lease term. We recorded $617 million and $447 million in revenue related to equipment we rent to patients for the years ended December 31, 2023 and 2022. Equipment rental revenue was not material in 2021. See Note 17 for disaggregation of revenue by segment and geography as we believe that best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. Cost of Goods Sold. In situations where we act as an agent in a sales arrangement and do not bear a significant portion of these risks, primarily for our outsourced logistics business, there is no cost of goods sold and all costs to provide the service to the customer are recorded in distribution, selling and administrative expenses. Within our Patient Direct segment, patient service equipment depreciation and the net book value of dispositions are classified in the Company’s consolidated statements of operations within cost of goods sold as the equipment is rented to patients as part of the Company’s primary operations. Depreciation expense for patient service equipment was $138 million and $88.7 million for the years ended December 31, 2023 and 2022. Equipment depreciation was not material for the year ended 2021. The net book value of patient service equipment dispositions were $36.3 million and $22.1 million for the years ended December 31, 2023 and 2022. We did not incur material dispositions during the year ended December 31, 2021. As a result of different practices of categorizing costs and different business models throughout our industry, our gross margins may not necessarily be comparable to other companies in our industry. Inventory valuation allowance adjustments, including for excess and obsolete inventory, are recorded as a charge to cost of goods sold. Distribution, Selling and Administrative (DS&A) Expenses. Shipping and Handling. Share-Based Compensation. Derivative Financial Instruments. All derivatives are carried at fair value in our consolidated balance sheets. The designation of a derivative instrument as a hedge and its ability to meet the hedge accounting criteria determine how we record the change in fair value of the derivative instrument in our consolidated financial statements. A derivative qualifies for hedge accounting if, at inception, we expect the derivative will be highly effective in offsetting the underlying hedged cash flows and we fulfill the hedge documentation standards at the time we enter into the derivative contract. We designate a hedge as a cash flow hedge, fair value hedge, or a net investment hedge based on the exposure we are hedging. For the effective portion of qualifying cash flow hedges, we record changes in fair value in other comprehensive income (OCI). We release the derivative’s gain or loss from OCI to match the timing of the underlying hedged items’ effect on earnings. We review the effectiveness of our hedging instruments quarterly, recognize current period hedge ineffectiveness immediately in earnings, and discontinue hedge accounting for any hedge that we no longer consider to be highly effective. We recognize changes in fair value for derivatives not designated as hedges or those not qualifying for hedge accounting in current period earnings. The cash flow impacts of the derivative instruments are included in our consolidated statements of cash flows as a component of operating or financing activities. Income Taxes. income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are provided if it is more likely than not that a deferred tax asset will not be realized. When we have claimed tax benefits that may be challenged by a tax authority, an estimate of the effect of these uncertain tax positions is recorded. It is our policy to provide for uncertain tax positions and the related interest and penalties based upon an assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent that the tax outcome of these uncertain tax positions changes, based on our assessment, such changes in estimate may impact the income tax provision in the period in which such determination is made. We earn a portion of our operating income in foreign jurisdictions outside the U.S. We are permanently reinvested in our foreign subsidiaries. Our policy election for global intangible low-taxed income is that we will record such taxes as a current period expense once incurred and will follow the tax law ordering approach. Fair Value Measurements. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued payroll and related liabilities reported in the consolidated balance sheets approximate fair value due to the short-term nature of these instruments. The fair value of debt is estimated based on quoted market prices or dealer quotes for the identical liability when traded as an asset in an active market (Level 1) or, if quoted market prices or dealer quotes are not available, on the borrowing rates currently available for loans with similar terms, credit ratings, and average remaining maturities (Level 2). See Note 9 for the fair value of debt. The fair value of our derivative contracts are determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. See Note 12 for the fair value of derivatives. Our acquisitions may include contingent consideration as part of the purchase price. The fair value of contingent consideration is estimated as of the acquisition date and at the end of each subsequent reporting period based on the present value of the contingent payments to be made using a weighted probability of possible payments (Level 3). Subsequent changes in fair value are recorded as adjustments to acquisition-related charges and intangible amortization within the consolidated statements of operations. Acquisition-Related Charges and Intangible Amortization . Exit and Realignment Charges estimable. These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis . Net (Loss) Income Per Share. Foreign Currency Translation. Business Combinations Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13 Financial Instruments - Credit Losses, Measurement of Credit Losses on Financial Instruments, which changes the way entities measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net earnings. Subsequent to the issuance of ASU No. 2016-13, the FASB issued various ASUs related to Credit Losses, Measurement of Credit Losses on Financial Instruments. These ASUs do not change the core principle of the guidance in ASU No. 2016-13. Instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard. We adopted ASU No. 2016-13 and subsequent amendments beginning January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted . Chief Operating Decision Maker (CODM), the title and position ​ In December 2023, the FASB Issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which will require additional annual income tax disclosures, including disclosure of reconciling items by jurisdiction and nature to the extent those items exceed a specified threshold. In addition, this ASU will require disclosure of income taxes paid, net of refunds received disaggregated by federal, state, and foreign and by jurisdiction if the amount is more than 5% of total income tax payments, net of refunds received. The amendments in this ASU are effective for us in annual periods beginning after December 15, 2024. The amendments in this ASU are required to be applied on a prospective basis and retrospective adoption is permitted. We expect this ASU to only impact our disclosures with no impacts to our results of operations, financial condition and cash flows.

Significant Risks and Uncertain

Significant Risks and Uncertainties	12 Months Ended
	Dec. 31, 2023
Risks and Uncertainties [Abstract]
Significant Risks and Uncertainties	Note 2—Significant Risks and Uncertainties Many of our hospital customers in the U.S. are represented by group purchasing organizations (GPOs) that contract with us for services on behalf of the GPO members. GPOs representing a significant portion of our business are Vizient, Premier, Inc. (Premier) and Health Trust Purchasing Group (HPG). Members of these GPOs have incentives to purchase from their primary selected distributor; however, they operate independently and are free to negotiate directly with distributors and manufacturers. For 2023, net revenue from hospitals under contract with these GPOs represented the following approximate percentages of our consolidated net revenue: Vizient—34%; Premier—19%; and HPG—11%. In 2023, 2022 and 2021, no sales of products of any individual suppliers exceeded 10% of our consolidated net revenue.

Acquisitions and Discontinued O

Acquisitions and Discontinued Operations	12 Months Ended
	Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Discontinued Operations	Note 3—Acquisition Acquisition. The following table presents the final fair value of the assets acquired and liabilities assumed recognized as of the Acquisition Date. The fair value and useful lives of tangible and intangible assets acquired were determine based on various valuation methods, including the income and cost approach, using several significant unobservable inputs including, but not limited to projected cash flows and a discount rate. These inputs are considered Level 3 inputs. ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value ​ as of Acquisition Date Assets acquired: ​ Current assets $ 139,560 Goodwill 1,251,347 Intangible assets 315,300 Other non-current assets 354,237 Total assets $ 2,060,444 Liabilities assumed: Current liabilities $ 247,276 Noncurrent liabilities 128,561 Total liabilities 375,837 Fair value of net assets acquired, net of cash $ 1,684,607 ​ Current assets acquired include $88.7 million in fair value of receivables, which reflects the approximate amount contractually owed. We are amortizing the fair value of acquired intangible assets, primarily customer relationships, including Payor and capitated relationships, and trade names over their estimated weighted average useful lives of one 15 years Goodwill of $1.3 billion, which we assigned to our Patient Direct segment, consists largely of expected opportunities to expand into new markets and further develop a presence in the home healthcare business. Approximately $33 million of the goodwill is deductible for income tax purposes. The following table provides pro forma results of net revenue and net loss for the year ended December 31, 2022 and 2021 as if Apria was acquired on January 1, 2021, based on the final purchase price allocation. The pro forma results below are not necessarily indicative of the results that would have been if the acquisition had occurred on the dates indicated, nor are the pro forma results indicative of results which may occur in the future. ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ ​ 2022 2021 Net revenue ​ $ 10,232,588 ​ $ 10,930,590 Net (loss) income ​ $ (97,687) ​ $ 286,466 ​ Pro forma net loss of $97.7 million for the year ended December 31, 2022 includes pro forma adjustments for interest expense of $20.8 million and amortization of intangible assets of $10.5 million. The pro forma net loss for the year ended December 31, 2022 also includes $39.4 million in seller transaction expenses and stock compensation expense associated with $108 million owed to the holders of Apria stock awards in connection with the Apria Acquisition. Revenue and net loss of Apria since the Acquisition Date included in the consolidated statement of operations for the year ended December 31, 2022 were $937 million and $3.3 million, respectively. Acquisition-related charges within acquisition-related charges and intangible amortization presented in our consolidated statements of operations were $17.5 million, $48.1 million, and $3.0 million for the years ended December 31, 2023, 2022, and 2021. These amounts are excluded from our segments’ operating income.

Merchandise Inventories

Merchandise Inventories	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Merchandise Inventories	Note 4—Merchandise Inventories At December 31, 2023 and 2022 we had net inventory of $1.1 billion and $1.3 billion, of which $718 million and $840 million were valued under LIFO, all of which relates to inventory in our Products & Healthcare Services segment. If LIFO inventories had been valued on a current cost or FIFO basis, they would have been greater by $233 million and $231 million as of December 31, 2023 and 2022. At December 31, 2023 and 2022, included in our inventory was $75.7 million and $84.4 million in raw materials, $61.5 million and $73.7 million in work in process and the remainder was finished goods. For the year ended December 31, 2022, primarily due to demand declines and builds in excess personal protective equipment (PPE), we increased our estimate of inventory valuation allowances. This change in estimate contributed to a $92.3 million (approximately $69.6 million, net of tax) valuation adjustment, or an approximate $0.93 and $0.91 impact per basic and diluted common share. For the year ended December 31, 2023, our inventory valuation allowances declined primarily due to inventory reductions, including excess PPE previously reserved. At December 31, 2023 and 2022 we had inventory valuation allowances of $78.2 million and $128 million.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Note 5—Property and Equipment, Net Property and equipment, net, consists of the following: ​ ​ ​ ​ ​ ​ ​ December 31, 2023 2022 Land and land improvements ​ $ 22,959 ​ $ 22,849 Buildings and leasehold improvements ​ 201,939 ​ 197,228 Machinery and equipment ​ 492,551 ​ 470,071 Patient service equipment ​ 362,192 ​ 324,007 Construction in progress ​ 10,728 ​ 14,400 Property and equipment, gross ​ 1,090,369 ​ 1,028,555 Accumulated depreciation and amortization ​ (546,397) ​ (450,286) Property and equipment, net ​ $ 543,972 ​ $ 578,269 ​ Depreciation and amortization expense for property and equipment and assets under finance leases was $188 million, $136 million, and $40.5 million for the years ended December 31, 2023, 2022, and 2021.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Note 6—Goodwill and Intangible Assets, Net The following table summarizes the changes in the carrying amount of goodwill through December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Products & ​ ​ ​ ​ ​ ​ ​ Healthcare ​ ​ ​ ​ ​ Patient Direct ​ Services ​ Consolidated Net carrying amount of goodwill, December 31, 2021 ​ $ 283,905 ​ $ 106,280 ​ $ 390,185 Currency translation adjustments ​ — ​ (2,713) ​ (2,713) Acquisition ​ ​ 1,249,765 ​ (532) ​ 1,249,233 Carrying amount of goodwill, December 31, 2022 ​ $ 1,533,670 ​ $ 103,035 ​ $ 1,636,705 Acquisition adjustment ​ 1,582 ​ — ​ 1,582 Currency translation adjustments ​ — ​ 559 ​ 559 Carrying amount of goodwill, December 31, 2023 ​ $ 1,535,252 ​ $ 103,594 ​ $ 1,638,846 ​ As of October 1, 2023, due to changes in our long-term financial plan assumptions, we elected to bypass the qualitative test and a quantitative goodwill impairment test was performed to compare the estimated fair value for all reporting units with goodwill to the respective carrying amount. No impairment of goodwill was recorded for the years ended December 31, 2023, 2022, and 2021. Intangible assets at December 31, 2023 and 2022 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ 2022 ​ ​ Customer ​ ​ Other Customer ​ ​ Other ​ ​ Relationships ​ Tradenames ​ Intangibles ​ Relationships ​ Tradenames ​ Intangibles Gross intangible assets ​ $ 433,750 ​ $ 202,000 ​ $ 73,958 ​ $ 447,107 ​ $ 202,000 ​ $ 73,181 Accumulated amortization ​ (236,791) ​ (69,655) ​ (41,427) ​ (197,540) ​ (50,094) ​ (29,612) Net intangible assets ​ $ 196,959 ​ $ 132,345 ​ $ 32,531 ​ $ 249,567 ​ $ 151,906 ​ $ 43,569 Weighted average useful life ​ 13 years ​ 10 years ​ 6 years ​ 13 years ​ 10 years ​ 6 years ​ At December 31, 2023 and 2022, $250 million and $308 million in net intangible assets were held in the Patient Direct segment and $112 million and $137 million were held in the Products & Healthcare Services segment. Amortization expense for intangible assets was $83.5 million for 2023, $78.8 million for 2022 and $39.8 million for 2021. As of December 31, 2023, based on the carrying value of intangible assets subject to amortization, estimated future amortization expense is as follows: ​ ​ ​ ​ Year ​ ​ 2024 ​ $ 64,594 2025 ​ 54,608 2026 ​ 50,255 2027 ​ 41,906 2028 ​ 32,081 Thereafter ​ ​ 118,391 Total future amortization ​ $ 361,835 ​

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	Note 7—Leases The components of lease expense were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ Classification 2023 2022 2021 Operating lease cost ​ DS&A Expenses ​ $ 109,942 ​ $ 81,520 ​ $ 59,397 Finance lease cost: ​ ​ ​ ​ Amortization of lease assets ​ DS&A Expenses ​ 2,151 ​ 2,755 ​ 1,098 Interest on lease liabilities ​ Interest expense, net ​ 1,232 ​ 1,516 ​ 1,255 Total finance lease cost ​ ​ ​ 3,383 ​ 4,271 ​ 2,353 Short-term lease cost ​ DS&A Expenses, Cost of goods sold ​ 8,271 ​ 4,129 ​ 871 Variable lease cost ​ DS&A Expenses, Cost of goods sold ​ 45,158 ​ 35,431 ​ 17,491 Total lease cost ​ ​ ​ $ 166,754 ​ $ 125,351 ​ $ 80,112 ​ Variable lease cost consists primarily of taxes, insurance, and common area or other maintenance costs for our leased facilities and patient service equipment which are paid as incurred. Supplemental balance sheet information is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ Classification 2023 2022 Assets: ​ ​ ​ ​ Operating lease assets ​ Operating lease assets ​ $ 296,533 ​ $ 280,665 Finance lease assets ​ Property and equipment, net ​ 8,477 ​ 10,194 Total lease assets ​ ​ ​ $ 305,010 ​ $ 290,859 Liabilities: ​ ​ ​ Current ​ ​ ​ Operating ​ Other current liabilities ​ $ 85,665 ​ $ 76,805 Finance ​ Current portion of long-term debt ​ 2,822 ​ 2,531 Noncurrent ​ ​ ​ Operating ​ Operating lease liabilities, excluding current portion ​ 222,429 ​ 215,469 Finance ​ Long-term debt, excluding current portion ​ 9,557 ​ 11,877 Total lease liabilities ​ ​ ​ $ 320,473 ​ $ 306,682 ​ The gross value recorded under finance leases was $22.2 million and $21.5 million with associated accumulated depreciation of $13.7 million and $11.3 million as of December 31, 2023 and 2022. Other information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ 2023 2022 2021 Supplemental cash flow information ​ ​ ​ ​ ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ Operating cash flows from operating and finance leases ​ $ 109,726 ​ $ 81,821 ​ $ 59,192 ​ Financing cash flows from finance leases ​ $ 2,523 ​ $ 2,850 ​ $ 1,199 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Right-of-use assets obtained in exchange for new operating and finance lease liabilities ​ $ 116,230 ​ $ 75,188 ​ $ 96,988 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (years) ​ ​ ​ ​ Operating leases ​ 3.9 ​ 4.3 ​ 4.9 ​ Finance leases ​ 4.3 ​ 5.2 ​ 6.4 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate ​ ​ ​ ​ Operating leases ​ 7.3 % 6.9 % 8.8 % Finance leases ​ 10.3 % 9.9 % 10.8 % ​ Maturities of lease liabilities as of December 31, 2023 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Finance Leases Total 2024 ​ $ 112,868 ​ $ 3,753 ​ $ 116,621 2025 ​ 92,510 ​ 3,657 ​ 96,167 2026 ​ 70,946 ​ 2,758 ​ 73,704 2027 ​ 46,597 ​ 2,302 ​ 48,899 2028 ​ 28,720 ​ 2,033 ​ 30,753 Thereafter ​ 17,650 ​ 511 ​ 18,161 Total lease payments ​ 369,291 ​ 15,014 ​ 384,305 Less: Interest ​ (61,197) ​ (2,635) ​ (63,832) Present value of lease liabilities ​ $ 308,094 ​ $ 12,379 ​ $ 320,473 (1)

Exit and Realignment Costs

Exit and Realignment Costs	12 Months Ended
	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Exit and Realignment Costs	​ Note 8—Exit and Realignment Costs We periodically incur exit and realignment and other charges associated with optimizing our operations which includes the consolidation of certain facilities, IT strategic initiatives, and other strategic actions. These charges also include costs associated with our Operating Model Realignment Program, which includes professional fees, severance and other costs to streamline functions and processes. Exit and realignment charges were $99.1 million, $6.9 million and $31.1 million for the years ended December 31, 2023, 2022 and 2021. These amounts are excluded from our segments’ operating income. We have incurred $92.2 million in charges under our Operating Model Realignment Program and IT strategic initiatives for the year ended December 31, 2023, which are included in the total exit and realignment charges above. We expect to incur material future costs relating to our Operating Model Realignment Program and IT strategic initiatives, which we are not able to reasonably estimate. The following table summarizes the activity related to exit and realignment cost accruals through December 31, 2023: ​ ​ ​ ​ ​ Total Accrued exit and realignment charges, December 31, 2020 ​ $ 3,146 Provision for exit and realignment activities: ​ Severance ​ 9,191 Information system restructuring costs ​ 4,752 Lease obligations ​ 440 Other ​ 5,564 Cash payments ​ (14,787) Accrued exit and realignment charges, December 31, 2021 ​ 8,306 Provision for exit and realignment activities: ​ Severance ​ 2,018 Other ​ 4,147 Cash payments ​ (13,502) Accrued exit and realignment charges, December 31, 2022 ​ 969 Provision for exit and realignment activities: ​ Severance ​ 11,556 Professional fees ​ ​ 63,699 Vendor contract and lease termination costs ​ ​ 6,198 IT strategic initiatives ​ ​ 8,649 Other ​ 5,619 Cash payments ​ (76,643) Accrued exit and realignment charges, December 31, 2023 ​ $ 20,047 ​ In addition to the exit and realignment accruals in the preceding table, we also incurred $3.4 million of costs that were expensed as incurred for the year ended December 31, 2023, which primarily related to charges associated with a lease termination and wind-down costs related to Fusion5. We also incurred $0.7 million and $11.2 million of costs that were expensed as incurred for the years ended December 31, 2022 and 2021, which primarily included wind-down costs related to Fusion5.

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	Note 9—Debt Debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 2022 ​ ​ Carrying Estimated Carrying Estimated December 31, ​ Amount ​ Fair Value ​ Amount ​ Fair Value 4.375% Senior Notes, due December 2024 ​ $ 171,232 ​ $ 168,754 ​ $ 245,510 ​ $ 237,772 Receivables Securitization Program ​ — ​ — ​ 93,142 ​ 96,000 Term Loan A ​ 387,591 ​ 390,668 ​ 490,816 ​ 485,000 4.500% Senior Notes, due March 2029 ​ 472,869 ​ 422,647 ​ 492,762 ​ 396,625 Term Loan B ​ 503,212 ​ 518,293 ​ 576,587 ​ 597,733 6.625% Senior Notes, due April 2030 ​ 540,445 ​ 529,472 ​ 585,180 ​ 516,060 Finance leases and other ​ 22,153 ​ 22,153 ​ 16,877 ​ 16,877 Total debt ​ 2,097,502 ​ 2,051,987 ​ 2,500,874 ​ 2,346,067 Less current maturities ​ (206,904) ​ (206,904) ​ (17,906) ​ (17,906) Long-term debt ​ $ 1,890,598 ​ $ 1,845,083 ​ $ 2,482,968 ​ $ 2,328,161 ​ We have $171 million of 4.375% senior notes due in December 2024 (the 2024 Notes), with interest payable semi-annually. The 2024 Notes were sold at 99.6% of the principal amount with an effective yield of 4.422%. We have the option to redeem the 2024 Notes in part or in whole prior to maturity at a redemption price equal to the greater of 100% of the principal amount or the present value of the remaining scheduled payments discounted at the applicable Benchmark Treasury Rate (as defined) plus 30 basis points. We used $73.5 million of cash to repurchase $74.7 million aggregate principal of the 2024 Notes during 2023. On March 29, 2022, we entered into a Security Agreement supplement pursuant to which the Security and Pledge Agreement (the Security Agreement), dated March 10, 2021 was supplemented to grant collateral on behalf of the holders of the 2024 Notes, and the parties secured under the credit agreements (the Secured Parties) including first priority liens and security interests in (a) all present and future shares of capital stock owned by the Grantors (as defined in the Security Agreement) in the Grantors’ present and future subsidiaries, subject to certain customary exceptions, and (b) all present and future personal property and assets of the Grantors, subject to certain exceptions. On March 29, 2022, we entered into an amendment to our Receivables Financing Agreement. The amended Receivables Financing Agreement has a maximum borrowing capacity of $450 million. The interest rate under the Receivables Financing Agreement is based on a spread over a benchmark SOFR rate (as described in the Fourth Amendment to the Receivables Financing Agreement, as further amended by the Fifth Amendment to the Receivables Financing Agreement). Under the Receivables Financing Agreement, certain of our accounts receivable balances are sold to our wholly owned special purpose entity, O&M Funding LLC. The Receivables Financing Agreement matures in March 2025. We had no borrowings at December 31, 2023 and $96.0 million outstanding at December 31, 2022 under our Receivables Financing Agreement. At December 31, 2023 and 2022, we had maximum revolving borrowing capacity of $450 million and $354 million available under our Receivables Financing Agreement. On March 29, 2022, we entered into a term loan credit agreement with an administrative agent and collateral agent and a syndicate of financial institutions, as lenders (the Credit Agreement) that provides for two new credit facilities (i) a $500 million Term Loan A facility (the Term Loan A), and (ii) a $600 million Term Loan B facility (the Term Loan B). The interest rate on the Term Loan A is based on the sum of either Term SOFR or the Base Rate and an Applicable Rate which varies depending on the current Debt Ratings or Total Leverage Ratio, determined as to whichever shall result in more favorable pricing to the Borrowers (each as defined in the Credit Agreement). The interest rate on the Term Loan B is based on either the Term SOFR or the Base Rate plus an Applicable Rate. The Term Loan A will mature in March 2027 and the Term Loan B will mature in March 2029. In addition to our scheduled principal payments of $9.4 million on the Term Loan A and $6.0 million on the Term Loan B, we made unscheduled principal payments of $97.5 million on Term Loan A and $72.5 million on Term Loan B during 2023. On March 10, 2021, we issued $500 million of 4.500% senior unsecured notes due in March 2029 (the 2029 Unsecured Notes), with interest payable semi-annually (the Notes Offering). The 2029 Unsecured Notes were sold at 100% of the principal amount with an effective yield of 4.500%. We may redeem all or part of the 2029 Unsecured Notes prior to March 31, 2024, at a price equal to 100% of the principal amount of the 2029 Unsecured Notes redeemed, plus accrued and unpaid interest, if any, to, but not including, the redemption date, plus a “make-whole” premium, as described in the Indenture dated March 10, 2021 (the Indenture). On or after March 31, 2024, we may redeem all or part of the 2029 Unsecured Notes at the applicable redemption prices described in the Indenture, plus accrued and unpaid interest, if any, to, but not including, the redemption date. We may also redeem up to 40% of the aggregate principal amount of the 2029 Unsecured Notes at any time prior to March 31, 2024, at a redemption price equal to 104.5% with an amount equal to or less than the net cash proceeds from certain equity offerings, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. We used $18.2 million of cash to repurchase $21.3 million aggregate principal of the 2029 Unsecured Notes during 2023. On March 29, 2022, we issued $600 million of 6.625% senior unsecured notes due in April 2030 (the 2030 Unsecured Notes), with interest payable semi-annually. The 2030 Unsecured Notes were sold at 100% of the principal amount with an effective yield of 6.625%. We may redeem all or part of the 2030 Unsecured Notes, prior to April 1, 2025, at a price equal to 100% of the principal amount of the 2030 Unsecured Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, plus a “make-whole” premium, as described in the Indenture dated March 29, 2022 (the New Indenture). From and after April 1, 2025, we may redeem all or part of the 2030 Unsecured Notes at the applicable redemption prices described in the New Indenture, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. We may also redeem up to 40% of the aggregate principal amount of the 2030 Unsecured Notes at any time prior to April 1, 2025, at a redemption price equal to 106.625% with an amount equal to or less than the net cash proceeds from certain equity offerings, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. We used $43.5 million of cash to repurchase $47.8 million aggregate principal of the 2030 Unsecured Notes during 2023. The 2029 Unsecured Notes and the 2030 Unsecured Notes are subordinated to any of our secured indebtedness, including indebtedness under our credit agreements. On March 29, 2022, we entered into an amendment to our revolving credit agreement, dated as of March 10, 2021 with an administrative agent and collateral agent and a syndicate of financial institutions, as lenders (Revolving Credit Agreement). The amendment (i) increased the aggregate revolving credit commitments under the Revolving Credit Agreement by $150 million, to an aggregate amount of $450 million and (ii) replaced the Eurocurrency Rate with the Adjusted Term SOFR Rate (each as defined in the Revolving Credit Agreement). The Revolving Credit Agreement matures in March 2027. At December 31, 2023 and 2022, our Revolving Credit Agreement was undrawn, and we had letters of credit, which reduce revolver availability, totaling $27.4 million and $27.9 million, leaving $423 million and $422 million available for borrowing. We also had letters of credit and bank guarantees, which support certain leased facilities as well as other normal business activities in the U.S. and Europe that were issued outside of the Revolving Credit Agreement for $3.0 million and $2.3 million as of December 31, 2023 and 2022. The Revolving Credit Agreement, the Credit Agreement, the Receivables Financing Agreement, the 2024 Notes, the 2029 Unsecured Notes, and the 2030 Unsecured Notes contain cross-default provisions which could result in the acceleration of payments due in the event of default of any of the related agreements. The terms of the applicable credit agreements also require us to maintain ratios for leverage and interest coverage, including on a pro forma basis in the event of an acquisition or divestiture. We were in compliance with our debt covenants at December 31, 2023. As of December 31, 2023, scheduled future principal payments of debt, excluding finance leases and other, were as follows: ​ ​ ​ ​ ​ Year ​ ​ 2024 ​ $ 199,197 2025 ​ 40,375 2026 ​ 43,500 2027 ​ 305,375 2028 ​ 6,000 2029 ​ 965,654 2030 ​ 552,189 ​ Of the $199 million due in 2024, $179 million is due in December 2024. Current maturities at December 31, 2023 include $171 million in principal payments on our 2024 Notes, $21.9 million in principal payments on our Term Loan A, $6.0 million in principal payments on our Term Loan B, and $7.7 million in current portion of finance leases and other.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Note 10—Share-Based Compensation We maintain a share-based compensation plan (the Plan) that is administered by the Our People & Culture Committee of the Board of Directors. The Plan allows us to award or grant to officers, directors and teammates incentive, non-qualified and deferred compensation stock options, stock appreciation rights (SARs), performance stock units and performance shares (collectively Performance Stock Awards (PSAs)), restricted stock units and restricted stock (collectively Restricted Stock Awards (RSAs)) and unrestricted stock. We use authorized and unissued common shares for grants of RSAs, SARs, PSAs or for stock option exercises. At December 31, 2023, approximately 3.6 million common shares were available for issuance under the Plan. RSAs under the Plan generally vest over one three five years three years We recognize the fair value of stock-based compensation awards, which is based upon the market price of the underlying common stock at the grant date, on a straight-line basis over the estimated requisite service period. RSAs are earned based on service conditions and PSAs are earned based on service conditions, performance conditions, market conditions, or any combination of these. The fair value of PSAs as of the date of grant is estimated assuming that performance goals will be achieved at target levels. If such goals are not probable of being met, or are probable of being met at different levels, recognized compensation cost is adjusted to reflect the change in estimated fair value. Total share-based compensation expense for December 31, 2023, 2022 and 2021 was $23.2 million, $21.0 million and $25.0 million with recognized tax benefits of $6.0 million, $5.5 million and $6.5 million. Unrecognized compensation cost related to nonvested RSAs, net of estimated forfeitures, was $28.4 million at December 31, 2023. This amount is expected to be recognized over a weighted-average period of 2.0 years, based on the maximum remaining vesting period required under the awards. Unrecognized compensation cost related to nonvested PSAs as of December 31, 2023 was $0.9 million and will be recognized primarily in 2024 and 2025 if the related performance targets are met at the current level expected. The following table summarizes the activity and value of nonvested RSAs and PSAs for the years ended December 31, 2023, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 2022 2021 ​ ​ Weighted ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ Average ​ ​ ​ Average ​ ​ ​ ​ Grant-date Fair ​ ​ ​ Grant-date Fair ​ ​ ​ Grant-date Fair ​ ​ Number of ​ Value ​ Number of ​ Value ​ Number of ​ Value ​ ​ Shares ​ Per Share ​ Shares ​ Per Share ​ Shares ​ Per Share Nonvested awards at beginning of year ​ 2,777 ​ $ 22.52 ​ 4,325 ​ $ 11.57 ​ 4,816 ​ $ 7.64 Granted ​ 3,137 ​ 18.34 ​ 2,745 ​ 19.10 ​ 2,758 ​ 14.10 Vested ​ (1,736) ​ 14.04 ​ (2,667) ​ 8.11 ​ (1,801) ​ 9.33 Forfeited ​ (977) ​ 26.82 ​ (1,626) ​ 11.25 ​ (1,448) ​ 6.10 Nonvested awards at end of year ​ 3,201 ​ 21.70 ​ 2,777 ​ 22.52 ​ 4,325 ​ 11.57 ​ The total fair value of RSAs and PSAs vesting during the years ended December 31, 2023, 2022 and 2021 was $24.4 million, $21.6 million and $16.8 million.

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Retirement Plans	Note 11—Retirement Plans Savings and Retirement Plans. U.S. Retirement Plans. The following table sets forth the U.S. Retirement Plan’s financial status and the amounts recognized in our consolidated balance sheets: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ 2022 Change in benefit obligation ​ ​ ​ Benefit obligation, beginning of year ​ $ 39,341 ​ $ 50,244 ​ Interest cost ​ 1,827 ​ 1,176 ​ Actuarial gain ​ (3,787) ​ (8,359) ​ Benefits paid ​ (3,322) ​ (3,720) ​ Benefit obligation, end of year ​ $ 34,059 ​ $ 39,341 ​ Change in plan assets ​ ​ ​ Fair value of plan assets, beginning of year ​ $ — ​ $ — ​ Employer contribution ​ 3,322 ​ 3,720 ​ Benefits paid ​ (3,322) ​ (3,720) ​ Fair value of plan assets, end of year ​ $ — ​ $ — ​ Funded status, end of year ​ $ (34,059) ​ $ (39,341) ​ Amounts recognized in the consolidated balance sheets ​ ​ ​ Other current liabilities ​ $ (2,975) ​ $ (3,604) ​ Other liabilities ​ (31,084) ​ (35,737) ​ Accumulated other comprehensive loss ​ 6,331 ​ 10,550 ​ Net amount recognized ​ $ (27,728) ​ $ (28,791) ​ Accumulated benefit obligation ​ $ 34,059 ​ $ 39,341 ​ Weighted average assumptions used to determine benefit obligation ​ ​ ​ Discount rate ​ 4.68 % 4.87 % Rate of increase in compensation levels ​ N/A ​ N/A ​ ​ Plan benefit obligations of the U.S. Retirement Plan were measured as of December 31, 2023 and 2022. Plan benefit obligations are determined using assumptions developed at the measurement date. The weighted average discount rate, which is used to calculate the present value of plan liabilities, is an estimate of the interest rate at which the plan liabilities could be effectively settled at the measurement date. When estimating the discount rate, we review yields available on high-quality, fixed-income debt instruments and use a yield curve model from which the discount rate is derived by applying the projected benefit payments under the plan to points on a published yield curve. The components of net periodic benefit cost for the U.S. Retirement Plan were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 ​ Interest cost ​ $ 1,827 ​ $ 1,176 ​ $ 1,080 ​ Recognized net actuarial loss ​ 431 ​ 923 ​ 1,199 ​ Net periodic benefit cost ​ $ 2,258 ​ $ 2,099 ​ $ 2,279 ​ Weighted average assumptions used to determine net periodic benefit cost ​ ​ ​ ​ Discount rate ​ 4.87 % 2.43 % 1.95 % Rate of increase in future compensation levels ​ N/A ​ N/A ​ N/A ​ ​ Amounts recognized for the U.S. Retirement Plan as a component of accumulated other comprehensive loss as of the end of the year that have not been recognized as a component of the net periodic benefit cost are presented in the following table. We expect to recognize approximately $0.2 million of the net actuarial loss reported in the following table as of December 31, 2023, as a component of net periodic benefit cost during 2024. ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 Net actuarial loss ​ $ (6,331) ​ $ (10,550) Deferred tax benefit ​ 3,867 ​ 4,964 Amounts included in accumulated other comprehensive loss, net of tax ​ $ (2,464) ​ $ (5,586) ​ As of December 31, 2023, the expected benefit payments required, based on the same assumptions used to measure our year-end benefit obligation, ​ ​ ​ ​ ​ Year ​ ​ 2024 ​ $ 2,942 2025 ​ 2,790 2026 ​ 2,627 2027 ​ 2,479 2028 ​ 2,333 2029-2033 ​ 9,234 ​ International Retirement Plans.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Note 12—Derivatives We are directly and indirectly affected by changes in foreign currency, which may adversely impact our financial performance and are referred to as “market risks.” When deemed appropriate, we use derivatives as a risk management tool to mitigate the potential impact of certain market risks. We do not enter into derivative financial instruments for trading purposes. We enter into foreign currency contracts to manage our foreign exchange exposure related to certain balance sheet items that do not meet the requirements for hedge accounting. These derivative instruments are adjusted to fair value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. We pay interest on our Credit Agreement which fluctuates based on changes in our benchmark interest rates. In order to mitigate the risk of increases in benchmark rates on our term loans, we entered into an interest rate swap agreement whereby we agree to exchange with the counterparty, at specified intervals, the difference between fixed and variable amounts calculated by reference to the notional amount. The interest rate swap was designated as a cash flow hedge. Cash flows related to the interest rate swap agreement are included in interest expense, net. We determine the fair value of our foreign currency derivatives and interest rate swaps based on observable market-based inputs or unobservable inputs that are corroborated by market data. We do not view the fair value of our derivatives in isolation, but rather in relation to the fair values or cash flows of the underlying exposure. All derivatives are carried at fair value in our consolidated balance sheets. We consider the risk of counterparty default to be minimal. We report cash flows from our hedging instruments in the same cash flow statement category as the hedged items. The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Notional ​ Derivative Assets Derivative Liabilities ​ Amount Maturity Date Classification Fair Value Classification Fair Value Cash flow hedge ​ ​ ​ ​ ​ ​ Interest rate swap ​ $ 350,000 ​ March 2027 Other assets, net ​ $ 8,447 ​ Other liabilities ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Economic (non-designated) hedges ​ ​ ​ ​ ​ Foreign currency contracts ​ $ 78,436 ​ January 2024 Other current assets ​ $ 1,043 ​ Other current liabilities ​ $ — ​ The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Notional ​ Derivative Assets Derivative Liabilities ​ Amount Maturity Date Classification Fair Value Classification Fair Value Cash flow hedge ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest rate swap ​ $ 400,000 ​ March 2027 ​ Other assets, net ​ $ 15,461 ​ Other liabilities ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Economic (non-designated) hedges ​ ​ ​ ​ ​ Foreign currency contracts ​ $ 58,321 ​ January 2023 Other current assets ​ $ 440 ​ Other current liabilities ​ $ 42 ​ The notional amount of the interest rate swap represents the amount in effect at the end of the period. Based on contractual terms, the notional amount will decrease in increments of $50.0 million on the last business day of March of each year until the maturity date. In March 2021, we terminated $300 million in notional value of interest rate swaps concurrent with the debt financing transaction. The balance of the fair value adjustments of $25.1 million, which related to these terminated interest rate swaps, within accumulated other comprehensive loss was reclassified to (gain) loss on extinguishment of debt within our consolidated statements of operations for the year ended December 31, 2021. The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of Gain Location of Gain Total Amount of Expense Amount of Gain/ ​ ​ Recognized in ​ Reclassified from ​ Line Items Presented in the ​ (Loss) Reclassified ​ ​ Other ​ Accumulated Other ​ Consolidated Statement of ​ from Accumulated ​ ​ Comprehensive ​ Comprehensive Loss ​ Operations in Which the ​ Other Comprehensive ​ ​ (Loss) Income into Income Effects are Recorded Loss into Income ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest rate swaps ​ $ 2,707 Interest expense, net ​ $ (157,915) ​ $ 9,720 ​ The amount of ineffectiveness associated with these contracts was immaterial for the periods presented. The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of ​ ​ Amount of Gain ​ Location of Gain ​ Total Amount of Expense ​ Gain/(Loss) ​ ​ Recognized in ​ Reclassified from ​ Line Items Presented in the ​ Reclassified from ​ ​ Other ​ Accumulated Other ​ Consolidated Statement of ​ Accumulated Other ​ ​ Comprehensive ​ Comprehensive Loss ​ Operations in Which the ​ Comprehensive Loss ​ ​ Income ​ into Income ​ Effects are Recorded ​ into Income ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest rate swaps ​ $ 14,814 Interest expense, net ​ $ (128,891) ​ $ (647) ​ The amount of ineffectiveness associated with these contracts was immaterial for the periods presented. The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of ​ ​ Amount of Gain Location of Gain Total Amount of Expense ​ Gain/(Loss) ​ ​ Recognized in ​ Reclassified from ​ Line Items Presented in the ​ Reclassified from ​ ​ Other ​ Accumulated Other ​ Consolidated Statement of ​ Accumulated Other ​ ​ Comprehensive ​ Comprehensive Loss ​ Operations in Which the ​ Comprehensive Loss ​ ​ Income ​ into Income ​ Effects are Recorded ​ into Income Interest rate swaps ​ $ 2,426 (Gain) loss on extinguishment of debt ​ $ (40,433) ​ $ (25,518) ​ The amount of ineffectiveness associated with these contracts was immaterial for the periods presented. For the years ended December 31, 2023, 2022 and 2021 we recognized a loss of $0.3 million, $0.9 million and $2.3 million, associated with our economic (non-designated) foreign currency contracts. We recorded the change in fair value of derivative instruments and the remeasurement adjustment of the foreign currency denominated asset or liability in other operating expense (income), net for our foreign exchange contracts.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 13—Income Taxes The components of net (loss) income before income taxes consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Net (loss) income before income taxes: ​ ​ ​ U.S. ​ $ (65,432) ​ $ (17,650) ​ $ 231,424 Foreign ​ 10,706 ​ 28,541 ​ 45,330 Net (loss) income before income taxes ​ $ (54,726) ​ $ 10,891 ​ $ 276,754 ​ The income tax provision (benefit) consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Current tax provision: ​ ​ ​ Federal ​ $ 3,887 ​ $ 1,090 ​ $ 54,087 State ​ 1,535 ​ 5,125 ​ 15,961 Foreign ​ 4,886 ​ 8,648 ​ 14,853 Total current tax provision ​ 10,308 ​ 14,863 ​ 84,901 Deferred tax benefit: ​ ​ ​ Federal ​ (18,081) ​ (8,671) ​ (22,046) State ​ (4,823) ​ (5,395) ​ (4,175) Foreign ​ (829) ​ (12,295) ​ (3,515) Total deferred tax benefit ​ (23,733) ​ (26,361) ​ (29,736) Total income tax benefit ​ $ (13,425) ​ $ (11,498) ​ $ 55,165 ​ A reconciliation of the federal statutory rate to our effective income tax rate is shown below: ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Federal statutory rate 21.0 % 21.0 % 21.0 % Increases (decreases) in the rate resulting from: ​ ​ Net capital loss on divestiture — % — % (1.0) % Tax reform — % — % (1.2) % Unrecognized tax benefits (2.6) % 10.2 % 0.1 % State income taxes, net of federal income tax impact 6.4 % (7.1) % 3.1 % Research and development credit 4.4 % (29.9) % (0.8) % Foreign income taxes (0.9) % 0.5 % 0.3 % Valuation allowance (0.5) % — % 1.1 % Restricted stock vestings (1.0) % (57.3) % (2.1) % Nondeductible Interest ​ (1.5) % 6.6 % 0.3 % Nondeductible compensation (3.6) % 28.9 % 1.0 % Foreign repatriation change (Thailand) — % (96.3) % — % Non-deductible transaction costs — % 19.5 % — % Foreign derived intangible income (FDII) 4.0 % — % (3.2) % Global intangible low-taxed income 0.7 % 5.0 % — % Other (1.9) % (6.7) % 1.3 % Effective income tax rate 24.5 % (105.6) % 19.9 % ​ The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below: ​ ​ ​ ​ ​ ​ ​ December 31, 2023 2022 Deferred tax assets: ​ ​ Employee benefit plans ​ $ 28,763 ​ $ 27,923 Accrued liabilities not currently deductible ​ 15,997 ​ 15,640 Finance charges ​ 2,173 ​ 2,143 Lease liabilities ​ 83,895 ​ 80,300 Allowance for losses on accounts receivable ​ 7,335 ​ 6,703 Net operating loss carryforwards ​ 41,165 ​ 55,992 Capital loss carryover ​ 30,034 ​ 30,034 Interest limitation ​ 13,082 ​ 19,890 Insurance ​ ​ 1,323 ​ ​ 20 R&D capitalized costs ​ 21,974 ​ 14,017 Other ​ 8,462 ​ 7,982 Total deferred tax assets ​ 254,203 ​ 260,644 Less: valuation allowances ​ (35,520) ​ (35,253) Net deferred tax assets ​ 218,683 ​ 225,391 Deferred tax liabilities: ​ ​ Merchandise inventories ​ 25,866 ​ 18,904 Goodwill ​ 5,426 ​ 4,151 Property, equipment and computer software ​ 69,411 ​ 91,983 Right-of-use assets ​ 79,303 ​ 75,623 Derivatives ​ 2,196 ​ 4,020 Intangible assets ​ 62,301 ​ 81,068 Other ​ 859 ​ 826 Total deferred tax liabilities ​ 245,362 ​ 276,575 Net deferred tax liability ​ $ (26,679) ​ $ (51,184) ​ The valuation allowances relate to deferred tax assets for U.S. federal and state capital loss carryforwards and net operating loss carryforwards in various state jurisdictions. The U.S. capital loss carryforward, which has a full valuation allowance, has an expiration date of five years. As of December 31, 2023, federal net operating losses of approximately $116 million are available to offset future federal taxable income. The entire $116 million of net operating losses have an unlimited carryforward period and will not expire. The capital loss and net operating loss carryforwards in various state jurisdictions have various expiration dates ranging from five years to an unlimited carryforward period. Based on management’s judgment using available evidence about historical and expected future taxable earnings, management believes it is more likely than not that we will realize the benefit of the existing deferred tax assets, net of valuation allowances, at December 31, 2023. Cash payments for income taxes, including interest, for 2023, 2022 and 2021 were $13.4 million, $38.1 million and $102 million. Cash tax refunds received for 2023, 2022 and 2021 were $19.7 million, $4.2 million and $2.5 million. A summary of the changes in the liability for unrecognized tax benefits from the beginning to the end of the reporting period is as follows: ​ ​ ​ ​ ​ ​ ​ ​ 2023 2022 Unrecognized tax benefits at January 1, ​ $ 22,499 ​ $ 21,385 Increases for positions taken during current period ​ 410 ​ 1,016 Increases for positions taken during prior periods ​ 13 ​ 325 Lapse of statute of limitations ​ (181) ​ (227) Unrecognized tax benefits at December 31, ​ $ 22,741 ​ $ 22,499 ​ Included in the liability for unrecognized tax benefits at December 31, 2023 and 2022, were $2.7 million of tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. These tax positions are temporary differences which do not impact the annual effective tax rate under deferred tax accounting. Any change in the deductibility period of these tax positions would impact the timing of cash payments to taxing jurisdictions. Unrecognized tax benefits of $20.0 million and $19.8 million at December 31, 2023 and 2022 would impact our effective tax rate if recognized and the remaining would not impact our effective tax rate. We recognize accrued interest and penalties related to unrecognized tax benefits. Accrued interest at December 31, 2023 and 2022 was $5.7 million and $3.9 million. The amounts recognized in interest expense for the years ended December 31, 2023, 2022 and 2021 were $1.7 million, $1.0 million and $0.3 million. There were no penalties accrued at December 31, 2023, 2022 and 2021 or recognized in 2023, 2022 and 2021. On August 26, 2020, we received a Notice of Proposed Adjustment (NOPA) from the Internal Revenue Service (IRS) regarding our 2015 and 2016 consolidated income tax returns. On June 30, 2021, we received a NOPA from the IRS regarding our 2017 and 2018 consolidated income tax returns. Within the NOPAs, the IRS has asserted that our taxable income for the aforementioned years should be higher based on their assessment of the appropriate amount of taxable income that we should report in the U.S. in connection with our sourcing of products by our foreign subsidiaries for sale in the U.S. by our domestic subsidiaries. Our amount of taxable income in the U.S. is based on our transfer pricing methodology, which has been consistently applied for all years subject to the NOPAs. We strongly disagree with the IRS position and will pursue all available administrative and judicial remedies, including those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. We regularly assess the likelihood of adverse outcomes resulting from examinations such as this to determine the adequacy of our tax reserves. We believe that we have adequately reserved for this matter and that the final adjudication of this matter will not have a material impact on our consolidated financial position, results of operations or cash flows. However, the ultimate outcome of disputes of this nature is uncertain, and if the IRS were to prevail on its assertions, the additional tax, interest, and any potential penalties could have a material adverse impact on our financial position, results of operations or cash flows. We file income tax returns in the U.S. federal and various state and foreign jurisdictions. Our U.S. federal income tax returns for the years 2015 through 2022 are subject to examination. Our income tax returns for U.S. state and local jurisdictions are generally open for the years 2019 through 2022; however, certain returns may be subject to examination for differing periods. The former owners are contractually obligated to indemnify us for all income tax liabilities incurred by Byram entities prior to its acquisition on August 1, 2017, and for all income tax liabilities incurred by the Halyard foreign entities located in Thailand, Mexico, and Honduras prior to its acquisition on April 30, 2018 .

Net Income per Common Share

Net Income per Common Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Net Income per Common Share	Note 14—Net (Loss) Income per Common Share The following summarizes the calculation of net (loss) income per common share attributable to common shareholders for the years ended December 31, 2023, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands, except per share data) ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Net (loss) income ​ $ (41,301) ​ $ 22,389 ​ $ 221,589 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares outstanding - basic ​ 75,785 ​ 74,496 ​ 72,744 Dilutive shares ​ — ​ 1,721 ​ 2,742 Weighted average shares outstanding - diluted ​ 75,785 ​ 76,217 ​ 75,486 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net (loss) income per common share: ​ ​ ​ Basic ​ $ (0.54) ​ $ 0.30 ​ $ 3.05 Diluted ​ $ (0.54) ​ $ 0.29 ​ $ 2.94 ​

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Accumulated Other Comprehensive Loss	Note 15—Accumulated Other Comprehensive (Loss) Income The following tables show the changes in accumulated other comprehensive (loss) income by component for the years ended December 31, 2023, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ Retirement ​ Translation ​ ​ ​ ​ ​ ​ ​ ​ Plans ​ Adjustments ​ Derivatives ​ Total Accumulated other comprehensive (loss) income, December 31, 2022 ​ $ (7,201) ​ $ (40,095) ​ $ 11,441 ​ $ (35,855) Other comprehensive income before reclassifications ​ 2,405 ​ 7,141 ​ 2,707 ​ 12,253 Income tax ​ (639) ​ — ​ (704) ​ (1,343) Other comprehensive income before reclassifications, net of tax ​ 1,766 ​ 7,141 ​ 2,003 ​ 10,910 Amounts reclassified from accumulated other comprehensive income (loss) ​ 431 ​ — ​ (9,720) ​ (9,289) Income tax ​ (111) ​ — ​ 2,527 ​ 2,416 Amounts reclassified from accumulated other comprehensive income (loss), net of tax ​ 320 ​ — ​ (7,193) ​ (6,873) Other comprehensive income (loss) ​ 2,086 ​ 7,141 ​ (5,190) ​ 4,037 Accumulated other comprehensive (loss) income, December 31, 2023 ​ $ (5,115) ​ $ (32,954) ​ $ 6,251 ​ $ (31,818) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ Retirement ​ Translation ​ ​ ​ ​ ​ ​ ​ ​ Plans ​ Adjustments ​ Derivatives ​ Total Accumulated other comprehensive loss, December 31, 2021 ​ $ (14,597) ​ $ (25,994) ​ $ — ​ $ (40,591) Other comprehensive income (loss) before reclassifications ​ 8,359 ​ (14,101) ​ 14,814 ​ 9,072 Income tax ​ (1,646) ​ — ​ (3,851) ​ (5,497) Other comprehensive income (loss) before reclassifications, net of tax ​ 6,713 ​ (14,101) ​ 10,963 ​ 3,575 Amounts reclassified from accumulated other comprehensive loss ​ 923 ​ — ​ 647 ​ 1,570 Income tax ​ (240) ​ — ​ (169) ​ (409) Amounts reclassified from accumulated other comprehensive loss, net of tax ​ 683 ​ — ​ 478 ​ 1,161 Other comprehensive income (loss) ​ 7,396 ​ (14,101) ​ 11,441 ​ 4,736 Accumulated other comprehensive income (loss), December 31, 2022 ​ $ (7,201) ​ $ (40,095) ​ $ 11,441 ​ $ (35,855) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ Retirement ​ Translation ​ ​ ​ ​ ​ ​ ​ ​ Plans ​ Adjustments ​ Derivatives ​ Total Accumulated other comprehensive loss, December 31, 2020 ​ $ (18,447) ​ $ (18) ​ $ (20,044) ​ $ (38,509) Other comprehensive income (loss) before reclassifications ​ 4,462 ​ (25,976) ​ 2,426 ​ (19,088) Income tax ​ (1,428) ​ — ​ (611) ​ (2,039) Other comprehensive income (loss) before reclassifications, net of tax ​ 3,034 ​ (25,976) ​ 1,815 ​ (21,127) Amounts reclassified from accumulated other comprehensive loss ​ 1,199 ​ — ​ 25,518 ​ 26,717 Income tax ​ (383) ​ — ​ (7,289) ​ (7,672) Amounts reclassified from accumulated other comprehensive loss, net of tax ​ 816 ​ — ​ 18,229 ​ 19,045 Other comprehensive income (loss) ​ 3,850 ​ (25,976) ​ 20,044 ​ (2,082) Accumulated other comprehensive loss, December 31, 2021 ​ $ (14,597) ​ $ (25,994) ​ $ — ​ $ (40,591) ​ We include amounts reclassified out of accumulated other comprehensive (loss) income related to defined benefit pension plans as a component of net periodic benefit cost recorded in Other expense, net.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Note 16— Commitments, Contingent Liabilities, and Legal Proceedings O&M Halyard N95 Mask FDA Release ​ On April 5, 2023, we received a communication from the National Institute for Occupational Safety & Health (NIOSH) that products from one lot of a model (No. 46827) of surgical N95 respirator manufactured by O&M Halyard did not pass laboratory tests for fluid resistance and for filtration efficiency, and that products from one lot of another model (No. 46727) did not pass fluid resistance testing, but did pass filtration efficiency testing. Our investigation determined that a limited number of lots were potentially implicated by the results of the NIOSH particulate filtration testing on model No. 46827, and that the vast majority of the products in those lots remained in our possession and under our control. Those lots have been segregated for disposal. We also determined that a limited quantity of products from one lot did reach the market. Although products from that lot passed internal and external follow-up testing for filtration efficiency, we initiated a voluntary recall of the lot on August 9, 2023 out of an abundance of caution. O&M Halyard has confirmed to NIOSH that the particle filtration issue was isolated to the identified lots. ​ On April 12, 2023, the U.S. Food and Drug Administration (FDA) recommended that consumers, health care providers, and facilities not use the two models (model numbers 46827 and 46727) of O&M Halyard surgical N95 respirators due to concerns about fluid resistance performance. In addition, the FDA also recommended against using certain of our surgical, procedure and pediatric face masks when fluid resistance is required. On or about that date, we voluntarily stopped the sale in the U.S. of the above-referenced surgical N95 respirators and similar models pending our investigation of the performance issues identified by the FDA and NIOSH. Regulatory bodies in other non-U.S. markets where we sell our facial protection products have inquired about the relevance of the FDA notification to products sold in their countries. The FDA updated its recommendation on April 21, 2023, to permit use of the model No. 46727 of Halyard N95 respirators when fluid resistance is not required. These items are included in our Products & Healthcare Services segment. ​ On September 29, 2023, the FDA updated its previous recommendation to consumers, health care providers and facilities regarding the above-referenced models of O&M Halyard surgical N95 respirators based on extensive testing and performance data provided by O&M Halyard. Specifically, the FDA stated that both O&M Halyard respirator models could be used according to the product labeling for respiratory and fluid barrier protection to the wearer (excluding the one lot of products that O&M Halyard voluntarily recalled on August 9, 2023). Following the FDA’s update, we published a user notice on our website announcing the resumption of sales and shipments of O&M Halyard surgical N95 respirators, noting that the data provided to the FDA and NIOSH demonstrated that our products provide the levels of particle filtration and fluid resistance for which they are rated. NIOSH reviewed and concurred with the facts set forth in our user notice published on September 29, 2023. While the FDA recommendation did not materially affect our results of operations for 2023, there is a risk that these matters and any other safety concerns could have a material adverse effect on our results of operations, financial condition, or cash flows, including as a result of a significant volume of customer product returns and/or recall of products, implementation of corrective action plans, and/or other costly remedial actions in the U.S. and elsewhere. In addition, these matters could potentially have other negative impacts including: government investigations and enforcement actions by the FDA or other U.S. or international regulators or governmental entities; the suspension or revocation of the authority to produce, distribute or sell products, and other sanctions; losses due to patient claims, including product liability claims and lawsuits; and customer claims related to their direct costs arising from supply disruption. ​ Other Litigation We are party to various legal claims that are ordinary and incidental to our business, including ones related to commercial disputes, employment, workers’ compensation, product liability, regulatory, cybersecurity and other matters. We maintain insurance coverage for cybersecurity, employment, product liability, workers’ compensation and other personal injury litigation matters, subject to policy limits, applicable deductibles and insurer solvency. From time to time, we establish estimated liabilities based upon periodic assessment of the potential outcomes of pending matters. Based on current knowledge and the advice of counsel, we believe that the liability recorded on the consolidated balance sheet as of December 31, 2023 for currently pending matters considered probable of loss, is sufficient. In addition, we believe that other currently pending matters are not reasonably possible to result in a material loss, as payment of the amounts claimed is remote, the claims are immaterial, individually and in the aggregate, or the claims are expected to be adequately covered by insurance, subject to policy limits, applicable deductibles, exclusions, and insurer solvency.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment Information	Note 17—Segment Information We periodically evaluate our application of accounting guidance for reportable segments and disclose information about reportable segments based on the way management organizes the enterprise for making operating decisions and assessing performance. We report our business under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment includes our U.S. distribution division (Medical Distribution), including outsourced logistics and value-added services business, and our Global Products division which manufactures and sources medical surgical products through our production and kitting operations. The Patient Direct segment includes our home healthcare divisions (Byram and Apria). We evaluate the performance of our segments based on their operating income excluding acquisition-related charges and intangible amortization and exit and realignment charges, along with other adjustments, that, either as a result of their nature or size, would not be expected to occur as part of our normal business operations on a regular basis. Segment assets exclude inter-segment account balances as we believe their inclusion would be misleading and not meaningful. The following tables present financial information by segment: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Net revenue: ​ ​ ​ Products & Healthcare Services ​ $ 7,781,395 ​ $ 7,898,397 ​ $ 8,825,646 Patient Direct ​ 2,552,572 ​ 2,057,078 ​ 959,669 Consolidated net revenue ​ $ 10,333,967 ​ $ 9,955,475 ​ $ 9,785,315 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income: ​ ​ ​ Products & Healthcare Services ​ $ 57,809 ​ $ 175,309 ​ $ 384,390 Patient Direct ​ 246,863 ​ 193,748 ​ 57,966 Acquisition-related charges and intangible amortization ​ (101,037) ​ (126,972) ​ (42,774) Exit and realignment charges ​ ​ (99,127) ​ ​ (6,897) ​ ​ (31,109) Inventory valuation adjustment (1) ​ — ​ (92,275) ​ — Consolidated operating income ​ $ 104,508 ​ $ 142,913 ​ $ 368,473 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization: ​ ​ ​ Products & Healthcare Services ​ $ 77,006 ​ $ 77,539 ​ $ 75,548 Patient Direct ​ 210,371 ​ 151,128 ​ 15,073 Consolidated depreciation and amortization ​ $ 287,377 ​ $ 228,667 ​ $ 90,621 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Share-based compensation: ​ ​ ​ ​ ​ ​ ​ ​ ​ Products & Healthcare Services ​ $ 15,078 ​ $ 19,681 ​ $ 22,476 Patient Direct ​ 5,864 ​ 820 ​ 937 Other (2) ​ ​ 2,276 ​ ​ 492 ​ ​ 1,603 Consolidated share-based compensation ​ $ 23,218 ​ $ 20,993 ​ $ 25,016 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures: ​ ​ ​ Products & Healthcare Services ​ $ 29,361 ​ $ 49,824 ​ $ 48,282 Patient Direct ​ 178,531 ​ 116,758 ​ 1,408 Consolidated capital expenditures ​ $ 207,892 ​ $ 166,582 ​ $ 49,690 (1) Relates to an inventory valuation adjustment in our Products & Healthcare Services segment, primarily associated with PPE inventory built up and a subsequent decline in demand as a result of the COVID-19 pandemic. (2) Other share-based compensation expense is captured within exit and realignment charges or acquisition-related charges for the years ended December 31 2023, 2022 and 2021. ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 2022 Total assets: ​ ​ Products & Healthcare Services ​ $ 2,359,825 ​ $ 2,809,600 Patient Direct ​ ​ 2,490,460 ​ ​ 2,507,216 Segment assets ​ ​ 4,850,285 ​ ​ 5,316,816 Cash and cash equivalents ​ 243,037 ​ 69,467 Consolidated total assets ​ $ 5,093,322 ​ $ 5,386,283 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Net revenue: ​ ​ ​ United States ​ $ 10,058,675 ​ $ 9,526,037 ​ $ 9,250,331 International ​ 275,292 ​ 429,438 ​ 534,984 Consolidated net revenue ​ $ 10,333,967 ​ $ 9,955,475 ​ $ 9,785,315 ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 2022 Long-lived assets: ​ ​ United States ​ $ 1,140,303 ​ $ 1,226,108 International ​ 109,504 ​ 116,524 Consolidated long-lived assets ​ $ 1,249,807 ​ $ 1,342,632 ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation. We report our business under two distinct segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment includes our United States (U.S.) distribution division (Medical Distribution), including outsourced logistics and value-added services, and Global Products division which manufactures and sources medical surgical products through our production and kitting operations. The Patient Direct segment includes our home healthcare divisions (Byram and Apria).
Reclassifications	Reclassifications.
Use of Estimates	Use of Estimates.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of those same amounts presented in the accompanying consolidated statements of cash flows. ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 December 31, 2022 Cash and cash equivalents ​ $ 243,037 ​ $ 69,467 Restricted cash included in Other current assets ​ 29,887 ​ — Restricted cash included in Other assets, net ​ ​ — ​ ​ 16,718 Total cash, cash equivalents, and restricted cash ​ $ 272,924 ​ $ 86,185 ​ Book overdrafts represent the amount of outstanding checks issued in excess of related bank balances and are included in accounts payable in our consolidated balance sheets, as they are similar to trade payables and are not subject to finance charges or interest. Changes in book overdrafts are classified as operating activities in our consolidated statements of cash flows.
Accounts Receivable, Net	Accounts Receivable, Net. Due to the nature of our industry and the reimbursement environment in which we operate in the Patient Direct segment, certain estimates are required to record total net revenues and accounts receivable at their net realizable values, including estimating variable consideration. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements, contractual terms, and the uncertainty of reimbursement amounts for certain services may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. We maintain valuation allowances based upon the expected collectability of accounts receivable. Our allowances include specific amounts for accounts that are likely to be uncollectible, such as customer bankruptcies and disputed amounts and general allowances for accounts that may become uncollectible. Allowances are estimated based on a number of factors, including industry trends, current economic conditions, creditworthiness of customers, age of the receivables, changes in customer payment patterns, and historical experience. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Allowances for losses on accounts receivable of $7.9 million and $9.1 million have been applied as reductions of accounts receivable at December 31, 2023 and 2022. On March 14, 2023, we entered into the RPA, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed $200 million are sold, on a limited-recourse basis, to the Purchaser in exchange for cash. As of December 31, 2023, there were a total of $124 million of uncollected accounts receivable that had been sold or removed from our consolidated balance sheet. We account for these transactions as sales with the sold receivables removed from our consolidated balance sheets. Under the RPA, we provide certain servicing and collection actions on behalf of the Purchaser; however, we do not maintain any beneficial interest in the accounts receivable sold. The RPA is separate and distinct from the accounts receivable securitization program (the Receivables Financing Agreement). Proceeds from the sales of accounts receivable are recorded as an increase to cash and cash equivalents and a reduction to accounts receivable, net of allowances in the consolidated balance sheets. Cash received from the sales of accounts receivable, net of payments made to the Purchaser, is reflected in the change in accounts receivable within cash provided by operating activities in the consolidated statements of cash flows. Total accounts receivable sold under the RPA and net cash proceeds were $1.4 billion during the year ended December 31, 2023. We collected $1.3 billion of the sold accounts receivable for the year ended December 31, 2023. The losses on sales of accounts receivable are recorded in other operating expense (income), net in the consolidated statements of operations and were $10.6 million for the year ended December 31, 2023.
Merchandise Inventories	Merchandise Inventories. We periodically evaluate whether inventory valuation allowance adjustments are required, which includes consideration of recent sales trends. In our evaluation, we review for expired or obsolete inventory and slow-moving inventory. We write down inventories which are considered excess and obsolete as a result of these assessments. Shifts in market trends and conditions, as well as changes in customer preferences and behavior could affect the value of our inventories.
Property and Equipment, net	Property and Equipment, net. three five one
Leases	Leases. one nine one three Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We elected the practical expedient to not separate lease and non-lease components for our leases. Operating lease assets and liabilities are recognized at commencement date based on the present value of unpaid lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments. We use the implicit rate when readily determinable. The right-of-use assets also include adjustments for any lease payments made and lease incentives received.
Goodwill	Goodwill. We evaluate goodwill for impairment annually, as of October 1, and if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not that the fair value does not exceed the carrying amount, then a quantitative test is performed. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. As of October 1, 2023, due to changes in our long-term financial plan assumptions, we elected to bypass the qualitative test and performed a quantitative goodwill impairment test for all reporting units with goodwill. We determine the estimated fair value of our reporting units by using an equally weighted combination of the income-based approach and the market-based approach. The income-based approach is dependent upon several significant assumptions and estimates regarding future period cash flows, including assumptions with respect to future sales growth and a terminal growth rate. In addition, a weighted average cost of capital (WACC) is used to discount future estimated cash flows to their present values. The WACC is based on externally observable data considering market participants’ cost of equity and debt, optimal capital structure and interest rates, as well as the risk and uncertainty with respect to the reporting unit and internally developed financial projections. Under the market-based approach, significant estimates and assumptions also include the selection of appropriate guideline public companies whose stock is actively traded in public markets and the determination of appropriate valuation multiples to apply to the reporting unit. Although we believe our assumptions and estimates are reasonable and appropriate, any significant adverse changes in one or a combination of key assumptions, including, but not limited to, a failure to meet our business plans or expected earnings and cash flows, unanticipated events and circumstances such as changes in assumptions about the duration and magnitude of increased supply chain expense, commodities costs or inflationary pressures and our planned efforts to mitigate such impacts, disruptions in the supply chain, estimated demand and selling prices for PPE or other products, an increase in the discount rate, a decrease in the terminal growth rate, increases in tax rates (including potential tax reform) or a significant change in industry or economic trends, may affect the accuracy or validity of such estimates and may result in goodwill impairment. We may be required to record a material charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill is determined, which could adversely affect our results of operations. No impairment of goodwill was recorded for the years ended December 31, 2023, 2022, and 2021.
Intangible Assets	Intangible Assets, net. one
Computer Software	Computer Software. three
Long-Lived Assets	Long-Lived Assets.
Self-Insurance Liabilities	Self-Insurance Liabilities. automobile liability claims are estimated using historical claims data and loss development factors. If the underlying facts and circumstances of existing claims change or historical trends are not indicative of future trends, then we may be required to adjust the liability and related expense accordingly. Self-insurance liabilities are included in other current liabilities and other liabilities in the consolidated balance sheets and were $26.0 million and $25.6 million in total at December 31, 2023 and 2022.
Revenue Recognition	Revenue Recognition. In our Products & Healthcare Services segment, under most of our distribution and product sales arrangements, our performance obligations are limited to delivery of products to a customer upon receipt of a purchase order. For these arrangements, we recognize revenue at the point in time when shipment is completed, as control passes to the customer upon product receipt. Our contracts sometime allow for forms of variable consideration including rebates, discounts, performance guarantees, and implicit price concessions. We estimate the amount of consideration to which we will be entitled in exchange for transferring the product or service to the customer under the expected value method as part of determining the sales transaction price using contractual terms, historical experience, and other operating trends. The amounts accrued for rebates due to customers, which are recorded in accounts receivable, net, were $81.3 million and $86.9 million at December 31, 2023 and 2022. In most cases, we record revenue gross, as we are the primary obligor. When we act as an agent in a sales arrangement and do not bear a significant portion of inventory risks, primarily for our outsourced logistics business, we record revenue net of product cost. Sales taxes collected from customers and remitted to governmental authorities are excluded from revenues. Within our Patient Direct segment, revenues are recognized under fee-for-service arrangements for equipment we rent to patients and sales of equipment, supplies and other items we sell to patients. Revenue that is generated from equipment that we rent to patients is primarily recognized over the noncancelable rental period, typically one month, and commences on delivery of the equipment to the patients. Revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. Rental revenue, less estimated adjustments, is recognized as earned on a straight-line basis over the noncancellable lease term. We recorded $617 million and $447 million in revenue related to equipment we rent to patients for the years ended December 31, 2023 and 2022. Equipment rental revenue was not material in 2021. See Note 17 for disaggregation of revenue by segment and geography as we believe that best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.
Cost of Goods Sold	Cost of Goods Sold. In situations where we act as an agent in a sales arrangement and do not bear a significant portion of these risks, primarily for our outsourced logistics business, there is no cost of goods sold and all costs to provide the service to the customer are recorded in distribution, selling and administrative expenses. Within our Patient Direct segment, patient service equipment depreciation and the net book value of dispositions are classified in the Company’s consolidated statements of operations within cost of goods sold as the equipment is rented to patients as part of the Company’s primary operations. Depreciation expense for patient service equipment was $138 million and $88.7 million for the years ended December 31, 2023 and 2022. Equipment depreciation was not material for the year ended 2021. The net book value of patient service equipment dispositions were $36.3 million and $22.1 million for the years ended December 31, 2023 and 2022. We did not incur material dispositions during the year ended December 31, 2021. As a result of different practices of categorizing costs and different business models throughout our industry, our gross margins may not necessarily be comparable to other companies in our industry. Inventory valuation allowance adjustments, including for excess and obsolete inventory, are recorded as a charge to cost of goods sold.
Distribution, Selling and Administrative (DS&A) Expenses	Distribution, Selling and Administrative (DS&A) Expenses.
Shipping and Handling	Shipping and Handling.
Share-Based Compensation	Share-Based Compensation.
Derivative Financial Instruments	Derivative Financial Instruments. All derivatives are carried at fair value in our consolidated balance sheets. The designation of a derivative instrument as a hedge and its ability to meet the hedge accounting criteria determine how we record the change in fair value of the derivative instrument in our consolidated financial statements. A derivative qualifies for hedge accounting if, at inception, we expect the derivative will be highly effective in offsetting the underlying hedged cash flows and we fulfill the hedge documentation standards at the time we enter into the derivative contract. We designate a hedge as a cash flow hedge, fair value hedge, or a net investment hedge based on the exposure we are hedging. For the effective portion of qualifying cash flow hedges, we record changes in fair value in other comprehensive income (OCI). We release the derivative’s gain or loss from OCI to match the timing of the underlying hedged items’ effect on earnings. We review the effectiveness of our hedging instruments quarterly, recognize current period hedge ineffectiveness immediately in earnings, and discontinue hedge accounting for any hedge that we no longer consider to be highly effective. We recognize changes in fair value for derivatives not designated as hedges or those not qualifying for hedge accounting in current period earnings. The cash flow impacts of the derivative instruments are included in our consolidated statements of cash flows as a component of operating or financing activities.
Income Taxes	Income Taxes. income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are provided if it is more likely than not that a deferred tax asset will not be realized. When we have claimed tax benefits that may be challenged by a tax authority, an estimate of the effect of these uncertain tax positions is recorded. It is our policy to provide for uncertain tax positions and the related interest and penalties based upon an assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent that the tax outcome of these uncertain tax positions changes, based on our assessment, such changes in estimate may impact the income tax provision in the period in which such determination is made. We earn a portion of our operating income in foreign jurisdictions outside the U.S. We are permanently reinvested in our foreign subsidiaries. Our policy election for global intangible low-taxed income is that we will record such taxes as a current period expense once incurred and will follow the tax law ordering approach.
Fair Value Measurements	Fair Value Measurements. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued payroll and related liabilities reported in the consolidated balance sheets approximate fair value due to the short-term nature of these instruments. The fair value of debt is estimated based on quoted market prices or dealer quotes for the identical liability when traded as an asset in an active market (Level 1) or, if quoted market prices or dealer quotes are not available, on the borrowing rates currently available for loans with similar terms, credit ratings, and average remaining maturities (Level 2). See Note 9 for the fair value of debt. The fair value of our derivative contracts are determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. See Note 12 for the fair value of derivatives. Our acquisitions may include contingent consideration as part of the purchase price. The fair value of contingent consideration is estimated as of the acquisition date and at the end of each subsequent reporting period based on the present value of the contingent payments to be made using a weighted probability of possible payments (Level 3). Subsequent changes in fair value are recorded as adjustments to acquisition-related charges and intangible amortization within the consolidated statements of operations.
Acquisition-Related Charges and Intangible Amortization	Acquisition-Related Charges and Intangible Amortization .
Exit and Realignment Charges	Exit and Realignment Charges estimable. These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis .
Net (Loss) Income Per Share	Net (Loss) Income Per Share.
Foreign Currency Translation	Foreign Currency Translation.
Business Combinations	Business Combinations
Recently Adopted and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-13 Financial Instruments - Credit Losses, Measurement of Credit Losses on Financial Instruments, which changes the way entities measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net earnings. Subsequent to the issuance of ASU No. 2016-13, the FASB issued various ASUs related to Credit Losses, Measurement of Credit Losses on Financial Instruments. These ASUs do not change the core principle of the guidance in ASU No. 2016-13. Instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard. We adopted ASU No. 2016-13 and subsequent amendments beginning January 1, 2023. The adoption did not have a material impact on our consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted . Chief Operating Decision Maker (CODM), the title and position ​ In December 2023, the FASB Issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which will require additional annual income tax disclosures, including disclosure of reconciling items by jurisdiction and nature to the extent those items exceed a specified threshold. In addition, this ASU will require disclosure of income taxes paid, net of refunds received disaggregated by federal, state, and foreign and by jurisdiction if the amount is more than 5% of total income tax payments, net of refunds received. The amendments in this ASU are effective for us in annual periods beginning after December 15, 2024. The amendments in this ASU are required to be applied on a prospective basis and retrospective adoption is permitted. We expect this ASU to only impact our disclosures with no impacts to our results of operations, financial condition and cash flows.
Segment Information	We periodically evaluate our application of accounting guidance for reportable segments and disclose information about reportable segments based on the way management organizes the enterprise for making operating decisions and assessing performance. We report our business under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment includes our U.S. distribution division (Medical Distribution), including outsourced logistics and value-added services business, and our Global Products division which manufactures and sources medical surgical products through our production and kitting operations. The Patient Direct segment includes our home healthcare divisions (Byram and Apria).

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of those same amounts presented in the accompanying consolidated statements of cash flows. ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 December 31, 2022 Cash and cash equivalents ​ $ 243,037 ​ $ 69,467 Restricted cash included in Other current assets ​ 29,887 ​ — Restricted cash included in Other assets, net ​ ​ — ​ ​ 16,718 Total cash, cash equivalents, and restricted cash ​ $ 272,924 ​ $ 86,185
Schedule restricted on cash and cash equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of those same amounts presented in the accompanying consolidated statements of cash flows. ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 December 31, 2022 Cash and cash equivalents ​ $ 243,037 ​ $ 69,467 Restricted cash included in Other current assets ​ 29,887 ​ — Restricted cash included in Other assets, net ​ ​ — ​ ​ 16,718 Total cash, cash equivalents, and restricted cash ​ $ 272,924 ​ $ 86,185

Acquisitions and Discontinued_2

Acquisitions and Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table presents the final fair value of the assets acquired and liabilities assumed recognized as of the Acquisition Date. The fair value and useful lives of tangible and intangible assets acquired were determine based on various valuation methods, including the income and cost approach, using several significant unobservable inputs including, but not limited to projected cash flows and a discount rate. These inputs are considered Level 3 inputs. ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value ​ as of Acquisition Date Assets acquired: ​ Current assets $ 139,560 Goodwill 1,251,347 Intangible assets 315,300 Other non-current assets 354,237 Total assets $ 2,060,444 Liabilities assumed: Current liabilities $ 247,276 Noncurrent liabilities 128,561 Total liabilities 375,837 Fair value of net assets acquired, net of cash $ 1,684,607 ​
Schedule of Pro Forma	The following table provides pro forma results of net revenue and net loss for the year ended December 31, 2022 and 2021 as if Apria was acquired on January 1, 2021, based on the final purchase price allocation. The pro forma results below are not necessarily indicative of the results that would have been if the acquisition had occurred on the dates indicated, nor are the pro forma results indicative of results which may occur in the future. ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ ​ 2022 2021 Net revenue ​ $ 10,232,588 ​ $ 10,930,590 Net (loss) income ​ $ (97,687) ​ $ 286,466

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment, net, consists of the following: ​ ​ ​ ​ ​ ​ ​ December 31, 2023 2022 Land and land improvements ​ $ 22,959 ​ $ 22,849 Buildings and leasehold improvements ​ 201,939 ​ 197,228 Machinery and equipment ​ 492,551 ​ 470,071 Patient service equipment ​ 362,192 ​ 324,007 Construction in progress ​ 10,728 ​ 14,400 Property and equipment, gross ​ 1,090,369 ​ 1,028,555 Accumulated depreciation and amortization ​ (546,397) ​ (450,286) Property and equipment, net ​ $ 543,972 ​ $ 578,269

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table summarizes the changes in the carrying amount of goodwill through December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Products & ​ ​ ​ ​ ​ ​ ​ Healthcare ​ ​ ​ ​ ​ Patient Direct ​ Services ​ Consolidated Net carrying amount of goodwill, December 31, 2021 ​ $ 283,905 ​ $ 106,280 ​ $ 390,185 Currency translation adjustments ​ — ​ (2,713) ​ (2,713) Acquisition ​ ​ 1,249,765 ​ (532) ​ 1,249,233 Carrying amount of goodwill, December 31, 2022 ​ $ 1,533,670 ​ $ 103,035 ​ $ 1,636,705 Acquisition adjustment ​ 1,582 ​ — ​ 1,582 Currency translation adjustments ​ — ​ 559 ​ 559 Carrying amount of goodwill, December 31, 2023 ​ $ 1,535,252 ​ $ 103,594 ​ $ 1,638,846
Intangible Assets	Intangible assets at December 31, 2023 and 2022 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 ​ 2022 ​ ​ Customer ​ ​ Other Customer ​ ​ Other ​ ​ Relationships ​ Tradenames ​ Intangibles ​ Relationships ​ Tradenames ​ Intangibles Gross intangible assets ​ $ 433,750 ​ $ 202,000 ​ $ 73,958 ​ $ 447,107 ​ $ 202,000 ​ $ 73,181 Accumulated amortization ​ (236,791) ​ (69,655) ​ (41,427) ​ (197,540) ​ (50,094) ​ (29,612) Net intangible assets ​ $ 196,959 ​ $ 132,345 ​ $ 32,531 ​ $ 249,567 ​ $ 151,906 ​ $ 43,569 Weighted average useful life ​ 13 years ​ 10 years ​ 6 years ​ 13 years ​ 10 years ​ 6 years
Schedule of estimated amortization expense	As of December 31, 2023, based on the carrying value of intangible assets subject to amortization, estimated future amortization expense is as follows: ​ ​ ​ ​ Year ​ ​ 2024 ​ $ 64,594 2025 ​ 54,608 2026 ​ 50,255 2027 ​ 41,906 2028 ​ 32,081 Thereafter ​ ​ 118,391 Total future amortization ​ $ 361,835 ​

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Components of Lease Expense	The components of lease expense were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ Classification 2023 2022 2021 Operating lease cost ​ DS&A Expenses ​ $ 109,942 ​ $ 81,520 ​ $ 59,397 Finance lease cost: ​ ​ ​ ​ Amortization of lease assets ​ DS&A Expenses ​ 2,151 ​ 2,755 ​ 1,098 Interest on lease liabilities ​ Interest expense, net ​ 1,232 ​ 1,516 ​ 1,255 Total finance lease cost ​ ​ ​ 3,383 ​ 4,271 ​ 2,353 Short-term lease cost ​ DS&A Expenses, Cost of goods sold ​ 8,271 ​ 4,129 ​ 871 Variable lease cost ​ DS&A Expenses, Cost of goods sold ​ 45,158 ​ 35,431 ​ 17,491 Total lease cost ​ ​ ​ $ 166,754 ​ $ 125,351 ​ $ 80,112 Other information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ 2023 2022 2021 Supplemental cash flow information ​ ​ ​ ​ ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ Operating cash flows from operating and finance leases ​ $ 109,726 ​ $ 81,821 ​ $ 59,192 ​ Financing cash flows from finance leases ​ $ 2,523 ​ $ 2,850 ​ $ 1,199 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Right-of-use assets obtained in exchange for new operating and finance lease liabilities ​ $ 116,230 ​ $ 75,188 ​ $ 96,988 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term (years) ​ ​ ​ ​ Operating leases ​ 3.9 ​ 4.3 ​ 4.9 ​ Finance leases ​ 4.3 ​ 5.2 ​ 6.4 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate ​ ​ ​ ​ Operating leases ​ 7.3 % 6.9 % 8.8 % Finance leases ​ 10.3 % 9.9 % 10.8 %
Assets And Liabilities, Lessee	Supplemental balance sheet information is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ Classification 2023 2022 Assets: ​ ​ ​ ​ Operating lease assets ​ Operating lease assets ​ $ 296,533 ​ $ 280,665 Finance lease assets ​ Property and equipment, net ​ 8,477 ​ 10,194 Total lease assets ​ ​ ​ $ 305,010 ​ $ 290,859 Liabilities: ​ ​ ​ Current ​ ​ ​ Operating ​ Other current liabilities ​ $ 85,665 ​ $ 76,805 Finance ​ Current portion of long-term debt ​ 2,822 ​ 2,531 Noncurrent ​ ​ ​ Operating ​ Operating lease liabilities, excluding current portion ​ 222,429 ​ 215,469 Finance ​ Long-term debt, excluding current portion ​ 9,557 ​ 11,877 Total lease liabilities ​ ​ ​ $ 320,473 ​ $ 306,682
Schedule of Maturities of Finance Lease Liabilities	Maturities of lease liabilities as of December 31, 2023 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Finance Leases Total 2024 ​ $ 112,868 ​ $ 3,753 ​ $ 116,621 2025 ​ 92,510 ​ 3,657 ​ 96,167 2026 ​ 70,946 ​ 2,758 ​ 73,704 2027 ​ 46,597 ​ 2,302 ​ 48,899 2028 ​ 28,720 ​ 2,033 ​ 30,753 Thereafter ​ 17,650 ​ 511 ​ 18,161 Total lease payments ​ 369,291 ​ 15,014 ​ 384,305 Less: Interest ​ (61,197) ​ (2,635) ​ (63,832) Present value of lease liabilities ​ $ 308,094 ​ $ 12,379 ​ $ 320,473 (1)
Schedule of Maturities of Operating Lease Liabilities	Maturities of lease liabilities as of December 31, 2023 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases Finance Leases Total 2024 ​ $ 112,868 ​ $ 3,753 ​ $ 116,621 2025 ​ 92,510 ​ 3,657 ​ 96,167 2026 ​ 70,946 ​ 2,758 ​ 73,704 2027 ​ 46,597 ​ 2,302 ​ 48,899 2028 ​ 28,720 ​ 2,033 ​ 30,753 Thereafter ​ 17,650 ​ 511 ​ 18,161 Total lease payments ​ 369,291 ​ 15,014 ​ 384,305 Less: Interest ​ (61,197) ​ (2,635) ​ (63,832) Present value of lease liabilities ​ $ 308,094 ​ $ 12,379 ​ $ 320,473 (1)

Exit and Realignment Costs (Tab

Exit and Realignment Costs (Tables)	12 Months Ended
	Dec. 31, 2023
Restructuring and Related Activities [Abstract]
Schedule of Exit and Realignment Cost Accrual Activity	The following table summarizes the activity related to exit and realignment cost accruals through December 31, 2023: ​ ​ ​ ​ ​ Total Accrued exit and realignment charges, December 31, 2020 ​ $ 3,146 Provision for exit and realignment activities: ​ Severance ​ 9,191 Information system restructuring costs ​ 4,752 Lease obligations ​ 440 Other ​ 5,564 Cash payments ​ (14,787) Accrued exit and realignment charges, December 31, 2021 ​ 8,306 Provision for exit and realignment activities: ​ Severance ​ 2,018 Other ​ 4,147 Cash payments ​ (13,502) Accrued exit and realignment charges, December 31, 2022 ​ 969 Provision for exit and realignment activities: ​ Severance ​ 11,556 Professional fees ​ ​ 63,699 Vendor contract and lease termination costs ​ ​ 6,198 IT strategic initiatives ​ ​ 8,649 Other ​ 5,619 Cash payments ​ (76,643) Accrued exit and realignment charges, December 31, 2023 ​ $ 20,047

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 2022 ​ ​ Carrying Estimated Carrying Estimated December 31, ​ Amount ​ Fair Value ​ Amount ​ Fair Value 4.375% Senior Notes, due December 2024 ​ $ 171,232 ​ $ 168,754 ​ $ 245,510 ​ $ 237,772 Receivables Securitization Program ​ — ​ — ​ 93,142 ​ 96,000 Term Loan A ​ 387,591 ​ 390,668 ​ 490,816 ​ 485,000 4.500% Senior Notes, due March 2029 ​ 472,869 ​ 422,647 ​ 492,762 ​ 396,625 Term Loan B ​ 503,212 ​ 518,293 ​ 576,587 ​ 597,733 6.625% Senior Notes, due April 2030 ​ 540,445 ​ 529,472 ​ 585,180 ​ 516,060 Finance leases and other ​ 22,153 ​ 22,153 ​ 16,877 ​ 16,877 Total debt ​ 2,097,502 ​ 2,051,987 ​ 2,500,874 ​ 2,346,067 Less current maturities ​ (206,904) ​ (206,904) ​ (17,906) ​ (17,906) Long-term debt ​ $ 1,890,598 ​ $ 1,845,083 ​ $ 2,482,968 ​ $ 2,328,161
Schedule of Maturities of Long-Term Debt	​ ​ ​ ​ ​ Year ​ ​ 2024 ​ $ 199,197 2025 ​ 40,375 2026 ​ 43,500 2027 ​ 305,375 2028 ​ 6,000 2029 ​ 965,654 2030 ​ 552,189

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Activity and Value of Nonvested RSAs and PSAs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 2022 2021 ​ ​ Weighted ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ ​ ​ Average ​ ​ ​ Average ​ ​ ​ ​ Grant-date Fair ​ ​ ​ Grant-date Fair ​ ​ ​ Grant-date Fair ​ ​ Number of ​ Value ​ Number of ​ Value ​ Number of ​ Value ​ ​ Shares ​ Per Share ​ Shares ​ Per Share ​ Shares ​ Per Share Nonvested awards at beginning of year ​ 2,777 ​ $ 22.52 ​ 4,325 ​ $ 11.57 ​ 4,816 ​ $ 7.64 Granted ​ 3,137 ​ 18.34 ​ 2,745 ​ 19.10 ​ 2,758 ​ 14.10 Vested ​ (1,736) ​ 14.04 ​ (2,667) ​ 8.11 ​ (1,801) ​ 9.33 Forfeited ​ (977) ​ 26.82 ​ (1,626) ​ 11.25 ​ (1,448) ​ 6.10 Nonvested awards at end of year ​ 3,201 ​ 21.70 ​ 2,777 ​ 22.52 ​ 4,325 ​ 11.57

Retirement Plans (Tables)

Retirement Plans (Tables)	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Domestic Retirement Plan's Financial Status and Amounts Recognized in Consolidated Balance Sheets	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ 2022 Change in benefit obligation ​ ​ ​ Benefit obligation, beginning of year ​ $ 39,341 ​ $ 50,244 ​ Interest cost ​ 1,827 ​ 1,176 ​ Actuarial gain ​ (3,787) ​ (8,359) ​ Benefits paid ​ (3,322) ​ (3,720) ​ Benefit obligation, end of year ​ $ 34,059 ​ $ 39,341 ​ Change in plan assets ​ ​ ​ Fair value of plan assets, beginning of year ​ $ — ​ $ — ​ Employer contribution ​ 3,322 ​ 3,720 ​ Benefits paid ​ (3,322) ​ (3,720) ​ Fair value of plan assets, end of year ​ $ — ​ $ — ​ Funded status, end of year ​ $ (34,059) ​ $ (39,341) ​ Amounts recognized in the consolidated balance sheets ​ ​ ​ Other current liabilities ​ $ (2,975) ​ $ (3,604) ​ Other liabilities ​ (31,084) ​ (35,737) ​ Accumulated other comprehensive loss ​ 6,331 ​ 10,550 ​ Net amount recognized ​ $ (27,728) ​ $ (28,791) ​ Accumulated benefit obligation ​ $ 34,059 ​ $ 39,341 ​ Weighted average assumptions used to determine benefit obligation ​ ​ ​ Discount rate ​ 4.68 % 4.87 % Rate of increase in compensation levels ​ N/A ​ N/A ​
Components of Net Periodic Benefit Cost for Domestic Retirement Plan	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 ​ Interest cost ​ $ 1,827 ​ $ 1,176 ​ $ 1,080 ​ Recognized net actuarial loss ​ 431 ​ 923 ​ 1,199 ​ Net periodic benefit cost ​ $ 2,258 ​ $ 2,099 ​ $ 2,279 ​ Weighted average assumptions used to determine net periodic benefit cost ​ ​ ​ ​ Discount rate ​ 4.87 % 2.43 % 1.95 % Rate of increase in future compensation levels ​ N/A ​ N/A ​ N/A ​
Amounts Recognized As Component of Accumulated Other Comprehensive Loss, Domestic	​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 Net actuarial loss ​ $ (6,331) ​ $ (10,550) Deferred tax benefit ​ 3,867 ​ 4,964 Amounts included in accumulated other comprehensive loss, net of tax ​ $ (2,464) ​ $ (5,586)
Expected Benefit Payments Required For Domestic Retirement Plan	​ ​ ​ ​ ​ Year ​ ​ 2024 ​ $ 2,942 2025 ​ 2,790 2026 ​ 2,627 2027 ​ 2,479 2028 ​ 2,333 2029-2033 ​ 9,234

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments	The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Notional ​ Derivative Assets Derivative Liabilities ​ Amount Maturity Date Classification Fair Value Classification Fair Value Cash flow hedge ​ ​ ​ ​ ​ ​ Interest rate swap ​ $ 350,000 ​ March 2027 Other assets, net ​ $ 8,447 ​ Other liabilities ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Economic (non-designated) hedges ​ ​ ​ ​ ​ Foreign currency contracts ​ $ 78,436 ​ January 2024 Other current assets ​ $ 1,043 ​ Other current liabilities ​ $ — ​ The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Notional ​ Derivative Assets Derivative Liabilities ​ Amount Maturity Date Classification Fair Value Classification Fair Value Cash flow hedge ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest rate swap ​ $ 400,000 ​ March 2027 ​ Other assets, net ​ $ 15,461 ​ Other liabilities ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Economic (non-designated) hedges ​ ​ ​ ​ ​ Foreign currency contracts ​ $ 58,321 ​ January 2023 Other current assets ​ $ 440 ​ Other current liabilities ​ $ 42
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of Gain Location of Gain Total Amount of Expense Amount of Gain/ ​ ​ Recognized in ​ Reclassified from ​ Line Items Presented in the ​ (Loss) Reclassified ​ ​ Other ​ Accumulated Other ​ Consolidated Statement of ​ from Accumulated ​ ​ Comprehensive ​ Comprehensive Loss ​ Operations in Which the ​ Other Comprehensive ​ ​ (Loss) Income into Income Effects are Recorded Loss into Income ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest rate swaps ​ $ 2,707 Interest expense, net ​ $ (157,915) ​ $ 9,720 ​ The amount of ineffectiveness associated with these contracts was immaterial for the periods presented. The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of ​ ​ Amount of Gain ​ Location of Gain ​ Total Amount of Expense ​ Gain/(Loss) ​ ​ Recognized in ​ Reclassified from ​ Line Items Presented in the ​ Reclassified from ​ ​ Other ​ Accumulated Other ​ Consolidated Statement of ​ Accumulated Other ​ ​ Comprehensive ​ Comprehensive Loss ​ Operations in Which the ​ Comprehensive Loss ​ ​ Income ​ into Income ​ Effects are Recorded ​ into Income ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest rate swaps ​ $ 14,814 Interest expense, net ​ $ (128,891) ​ $ (647) ​ The amount of ineffectiveness associated with these contracts was immaterial for the periods presented. The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amount of ​ ​ Amount of Gain Location of Gain Total Amount of Expense ​ Gain/(Loss) ​ ​ Recognized in ​ Reclassified from ​ Line Items Presented in the ​ Reclassified from ​ ​ Other ​ Accumulated Other ​ Consolidated Statement of ​ Accumulated Other ​ ​ Comprehensive ​ Comprehensive Loss ​ Operations in Which the ​ Comprehensive Loss ​ ​ Income ​ into Income ​ Effects are Recorded ​ into Income Interest rate swaps ​ $ 2,426 (Gain) loss on extinguishment of debt ​ $ (40,433) ​ $ (25,518) ​ The amount of ineffectiveness associated with these contracts was immaterial for the periods presented.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Components of Income before Income Taxes	The components of net (loss) income before income taxes consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Net (loss) income before income taxes: ​ ​ ​ U.S. ​ $ (65,432) ​ $ (17,650) ​ $ 231,424 Foreign ​ 10,706 ​ 28,541 ​ 45,330 Net (loss) income before income taxes ​ $ (54,726) ​ $ 10,891 ​ $ 276,754
Income Tax Provision	The income tax provision (benefit) consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Current tax provision: ​ ​ ​ Federal ​ $ 3,887 ​ $ 1,090 ​ $ 54,087 State ​ 1,535 ​ 5,125 ​ 15,961 Foreign ​ 4,886 ​ 8,648 ​ 14,853 Total current tax provision ​ 10,308 ​ 14,863 ​ 84,901 Deferred tax benefit: ​ ​ ​ Federal ​ (18,081) ​ (8,671) ​ (22,046) State ​ (4,823) ​ (5,395) ​ (4,175) Foreign ​ (829) ​ (12,295) ​ (3,515) Total deferred tax benefit ​ (23,733) ​ (26,361) ​ (29,736) Total income tax benefit ​ $ (13,425) ​ $ (11,498) ​ $ 55,165
Reconciliation of Federal Statutory Rate to Effective Income Tax Rate	A reconciliation of the federal statutory rate to our effective income tax rate is shown below: ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Federal statutory rate 21.0 % 21.0 % 21.0 % Increases (decreases) in the rate resulting from: ​ ​ Net capital loss on divestiture — % — % (1.0) % Tax reform — % — % (1.2) % Unrecognized tax benefits (2.6) % 10.2 % 0.1 % State income taxes, net of federal income tax impact 6.4 % (7.1) % 3.1 % Research and development credit 4.4 % (29.9) % (0.8) % Foreign income taxes (0.9) % 0.5 % 0.3 % Valuation allowance (0.5) % — % 1.1 % Restricted stock vestings (1.0) % (57.3) % (2.1) % Nondeductible Interest ​ (1.5) % 6.6 % 0.3 % Nondeductible compensation (3.6) % 28.9 % 1.0 % Foreign repatriation change (Thailand) — % (96.3) % — % Non-deductible transaction costs — % 19.5 % — % Foreign derived intangible income (FDII) 4.0 % — % (3.2) % Global intangible low-taxed income 0.7 % 5.0 % — % Other (1.9) % (6.7) % 1.3 % Effective income tax rate 24.5 % (105.6) % 19.9 %
Tax Effects On Deferred Tax Assets And Deferred Tax Liabilities	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below: ​ ​ ​ ​ ​ ​ ​ December 31, 2023 2022 Deferred tax assets: ​ ​ Employee benefit plans ​ $ 28,763 ​ $ 27,923 Accrued liabilities not currently deductible ​ 15,997 ​ 15,640 Finance charges ​ 2,173 ​ 2,143 Lease liabilities ​ 83,895 ​ 80,300 Allowance for losses on accounts receivable ​ 7,335 ​ 6,703 Net operating loss carryforwards ​ 41,165 ​ 55,992 Capital loss carryover ​ 30,034 ​ 30,034 Interest limitation ​ 13,082 ​ 19,890 Insurance ​ ​ 1,323 ​ ​ 20 R&D capitalized costs ​ 21,974 ​ 14,017 Other ​ 8,462 ​ 7,982 Total deferred tax assets ​ 254,203 ​ 260,644 Less: valuation allowances ​ (35,520) ​ (35,253) Net deferred tax assets ​ 218,683 ​ 225,391 Deferred tax liabilities: ​ ​ Merchandise inventories ​ 25,866 ​ 18,904 Goodwill ​ 5,426 ​ 4,151 Property, equipment and computer software ​ 69,411 ​ 91,983 Right-of-use assets ​ 79,303 ​ 75,623 Derivatives ​ 2,196 ​ 4,020 Intangible assets ​ 62,301 ​ 81,068 Other ​ 859 ​ 826 Total deferred tax liabilities ​ 245,362 ​ 276,575 Net deferred tax liability ​ $ (26,679) ​ $ (51,184)
Reconciliation of Changes In Unrecognized Tax Benefits	A summary of the changes in the liability for unrecognized tax benefits from the beginning to the end of the reporting period is as follows: ​ ​ ​ ​ ​ ​ ​ ​ 2023 2022 Unrecognized tax benefits at January 1, ​ $ 22,499 ​ $ 21,385 Increases for positions taken during current period ​ 410 ​ 1,016 Increases for positions taken during prior periods ​ 13 ​ 325 Lapse of statute of limitations ​ (181) ​ (227) Unrecognized tax benefits at December 31, ​ $ 22,741 ​ $ 22,499

Net Income per Common Share (Ta

Net Income per Common Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Summary of Calculation of Net Income Per Share	The following summarizes the calculation of net (loss) income per common share attributable to common shareholders for the years ended December 31, 2023, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (in thousands, except per share data) ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Net (loss) income ​ $ (41,301) ​ $ 22,389 ​ $ 221,589 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares outstanding - basic ​ 75,785 ​ 74,496 ​ 72,744 Dilutive shares ​ — ​ 1,721 ​ 2,742 Weighted average shares outstanding - diluted ​ 75,785 ​ 76,217 ​ 75,486 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net (loss) income per common share: ​ ​ ​ Basic ​ $ (0.54) ​ $ 0.30 ​ $ 3.05 Diluted ​ $ (0.54) ​ $ 0.29 ​ $ 2.94

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following tables show the changes in accumulated other comprehensive (loss) income by component for the years ended December 31, 2023, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ Retirement ​ Translation ​ ​ ​ ​ ​ ​ ​ ​ Plans ​ Adjustments ​ Derivatives ​ Total Accumulated other comprehensive (loss) income, December 31, 2022 ​ $ (7,201) ​ $ (40,095) ​ $ 11,441 ​ $ (35,855) Other comprehensive income before reclassifications ​ 2,405 ​ 7,141 ​ 2,707 ​ 12,253 Income tax ​ (639) ​ — ​ (704) ​ (1,343) Other comprehensive income before reclassifications, net of tax ​ 1,766 ​ 7,141 ​ 2,003 ​ 10,910 Amounts reclassified from accumulated other comprehensive income (loss) ​ 431 ​ — ​ (9,720) ​ (9,289) Income tax ​ (111) ​ — ​ 2,527 ​ 2,416 Amounts reclassified from accumulated other comprehensive income (loss), net of tax ​ 320 ​ — ​ (7,193) ​ (6,873) Other comprehensive income (loss) ​ 2,086 ​ 7,141 ​ (5,190) ​ 4,037 Accumulated other comprehensive (loss) income, December 31, 2023 ​ $ (5,115) ​ $ (32,954) ​ $ 6,251 ​ $ (31,818) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ Retirement ​ Translation ​ ​ ​ ​ ​ ​ ​ ​ Plans ​ Adjustments ​ Derivatives ​ Total Accumulated other comprehensive loss, December 31, 2021 ​ $ (14,597) ​ $ (25,994) ​ $ — ​ $ (40,591) Other comprehensive income (loss) before reclassifications ​ 8,359 ​ (14,101) ​ 14,814 ​ 9,072 Income tax ​ (1,646) ​ — ​ (3,851) ​ (5,497) Other comprehensive income (loss) before reclassifications, net of tax ​ 6,713 ​ (14,101) ​ 10,963 ​ 3,575 Amounts reclassified from accumulated other comprehensive loss ​ 923 ​ — ​ 647 ​ 1,570 Income tax ​ (240) ​ — ​ (169) ​ (409) Amounts reclassified from accumulated other comprehensive loss, net of tax ​ 683 ​ — ​ 478 ​ 1,161 Other comprehensive income (loss) ​ 7,396 ​ (14,101) ​ 11,441 ​ 4,736 Accumulated other comprehensive income (loss), December 31, 2022 ​ $ (7,201) ​ $ (40,095) ​ $ 11,441 ​ $ (35,855) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Currency ​ ​ ​ ​ ​ ​ Retirement ​ Translation ​ ​ ​ ​ ​ ​ ​ ​ Plans ​ Adjustments ​ Derivatives ​ Total Accumulated other comprehensive loss, December 31, 2020 ​ $ (18,447) ​ $ (18) ​ $ (20,044) ​ $ (38,509) Other comprehensive income (loss) before reclassifications ​ 4,462 ​ (25,976) ​ 2,426 ​ (19,088) Income tax ​ (1,428) ​ — ​ (611) ​ (2,039) Other comprehensive income (loss) before reclassifications, net of tax ​ 3,034 ​ (25,976) ​ 1,815 ​ (21,127) Amounts reclassified from accumulated other comprehensive loss ​ 1,199 ​ — ​ 25,518 ​ 26,717 Income tax ​ (383) ​ — ​ (7,289) ​ (7,672) Amounts reclassified from accumulated other comprehensive loss, net of tax ​ 816 ​ — ​ 18,229 ​ 19,045 Other comprehensive income (loss) ​ 3,850 ​ (25,976) ​ 20,044 ​ (2,082) Accumulated other comprehensive loss, December 31, 2021 ​ $ (14,597) ​ $ (25,994) ​ $ — ​ $ (40,591)

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Financial Information by Segment	The following tables present financial information by segment: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Net revenue: ​ ​ ​ Products & Healthcare Services ​ $ 7,781,395 ​ $ 7,898,397 ​ $ 8,825,646 Patient Direct ​ 2,552,572 ​ 2,057,078 ​ 959,669 Consolidated net revenue ​ $ 10,333,967 ​ $ 9,955,475 ​ $ 9,785,315 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating income: ​ ​ ​ Products & Healthcare Services ​ $ 57,809 ​ $ 175,309 ​ $ 384,390 Patient Direct ​ 246,863 ​ 193,748 ​ 57,966 Acquisition-related charges and intangible amortization ​ (101,037) ​ (126,972) ​ (42,774) Exit and realignment charges ​ ​ (99,127) ​ ​ (6,897) ​ ​ (31,109) Inventory valuation adjustment (1) ​ — ​ (92,275) ​ — Consolidated operating income ​ $ 104,508 ​ $ 142,913 ​ $ 368,473 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization: ​ ​ ​ Products & Healthcare Services ​ $ 77,006 ​ $ 77,539 ​ $ 75,548 Patient Direct ​ 210,371 ​ 151,128 ​ 15,073 Consolidated depreciation and amortization ​ $ 287,377 ​ $ 228,667 ​ $ 90,621 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Share-based compensation: ​ ​ ​ ​ ​ ​ ​ ​ ​ Products & Healthcare Services ​ $ 15,078 ​ $ 19,681 ​ $ 22,476 Patient Direct ​ 5,864 ​ 820 ​ 937 Other (2) ​ ​ 2,276 ​ ​ 492 ​ ​ 1,603 Consolidated share-based compensation ​ $ 23,218 ​ $ 20,993 ​ $ 25,016 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Capital expenditures: ​ ​ ​ Products & Healthcare Services ​ $ 29,361 ​ $ 49,824 ​ $ 48,282 Patient Direct ​ 178,531 ​ 116,758 ​ 1,408 Consolidated capital expenditures ​ $ 207,892 ​ $ 166,582 ​ $ 49,690
Consolidated Total Assets	​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 2022 Total assets: ​ ​ Products & Healthcare Services ​ $ 2,359,825 ​ $ 2,809,600 Patient Direct ​ ​ 2,490,460 ​ ​ 2,507,216 Segment assets ​ ​ 4,850,285 ​ ​ 5,316,816 Cash and cash equivalents ​ 243,037 ​ 69,467 Consolidated total assets ​ $ 5,093,322 ​ $ 5,386,283
Financial Information by Geographic Area	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, 2023 2022 2021 Net revenue: ​ ​ ​ United States ​ $ 10,058,675 ​ $ 9,526,037 ​ $ 9,250,331 International ​ 275,292 ​ 429,438 ​ 534,984 Consolidated net revenue ​ $ 10,333,967 ​ $ 9,955,475 ​ $ 9,785,315 ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 2022 Long-lived assets: ​ ​ United States ​ $ 1,140,303 ​ $ 1,226,108 International ​ 109,504 ​ 116,524 Consolidated long-lived assets ​ $ 1,249,807 ​ $ 1,342,632 ​

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) country segment	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 14, 2023 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of countries in which entity operates | country	80
Number of operating segments | segment	2
Number of reportable segments | segment	2
Allowances for losses on accounts receivable	$ 7,900	$ 9,100
Uncollected accounts receivable	124,000
Net cash proceeds	1,400,000
Accounts receivable collected	1,300,000
Losses on sale of accounts receivable	(10,600)
Impairment of goodwill	0	0	$ 0
Capitalized computer software, net	47,500	38,700
Software amortization	16,100	14,000	10,300
Impairment of long-lived assets	0	0	0
Self-insurance liabilities	26,000	25,600
Contract with customer, liability	81,300	86,900
Depreciation	188,000	136,000	40,500
Net book value of dispositions			0
Research and development expense	13,200	11,800	12,100
Distribution, selling and administrative expenses	1,813,559	1,554,821	1,077,064
Rental Equipment
Summary Of Significant Accounting Policies [Line Items]
Revenue related to equipment			0
Rental Equipment | Patient Direct
Summary Of Significant Accounting Policies [Line Items]
Revenue related to equipment	617,000	447,000
Shipping and Handling
Summary Of Significant Accounting Policies [Line Items]
Distribution, selling and administrative expenses	$ 641,000	$ 581,000	445,000
Other Intangibles
Summary Of Significant Accounting Policies [Line Items]
Useful life	6 years	6 years
Minimum
Summary Of Significant Accounting Policies [Line Items]
Operating lease, renewal term	1 year
Minimum | Software technology
Summary Of Significant Accounting Policies [Line Items]
Computer software, useful life	3 years
Minimum | Other Intangibles
Summary Of Significant Accounting Policies [Line Items]
Useful life	1 year
Maximum
Summary Of Significant Accounting Policies [Line Items]
Uncollected accounts receivable				$ 200,000
Operating lease, term of contract	12 months
Operating lease, renewal term	5 years
Maximum | Software technology
Summary Of Significant Accounting Policies [Line Items]
Computer software, useful life	10 years
Maximum | Other Intangibles
Summary Of Significant Accounting Policies [Line Items]
Useful life	15 years
Warehouse equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life (in years)	3 years
Warehouse equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life (in years)	15 years
Buildings | Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life (in years)	5 years
Buildings | Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life (in years)	40 years
Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life (in years)	1 year
Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life (in years)	10 years
Leaseholds and Land Improvements | Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment useful life (in years)	15 years
Warehouse Facilities | Minimum
Summary Of Significant Accounting Policies [Line Items]
Operating lease, term of contract	1 year
Warehouse Facilities | Maximum
Summary Of Significant Accounting Policies [Line Items]
Operating lease, term of contract	9 years
Transportation And Material Handling Equipment | Minimum
Summary Of Significant Accounting Policies [Line Items]
Lessor, operating lease, term of contract	3 years
Transportation And Material Handling Equipment | Maximum
Summary Of Significant Accounting Policies [Line Items]
Lessor, operating lease, term of contract	10 years
Patient service equipment
Summary Of Significant Accounting Policies [Line Items]
Depreciation			$ 0
Patient service equipment | Patient Direct
Summary Of Significant Accounting Policies [Line Items]
Depreciation	$ 138,000	$ 88,700
Net book value of dispositions	36,300	$ 22,100
Master Receivables Purchase Agreement
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 13,500

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 243,037	$ 69,467
Restricted cash included in Other current assets	29,887	0
Restricted cash included in Other assets, net	0	16,718
Total cash, cash equivalents and restricted cash	$ 272,924	$ 86,185	$ 72,035	$ 134,506

Significant Risks And Uncerta_2

Significant Risks And Uncertainties - Additional Information (Details) - Revenue Benchmark - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2023
Vizient
Unusual Risk or Uncertainty [Line Items]
Customer revenue as a percentage of net revenue	34%
Premier
Unusual Risk or Uncertainty [Line Items]
Customer revenue as a percentage of net revenue	19%
HPG
Unusual Risk or Uncertainty [Line Items]
Customer revenue as a percentage of net revenue	11%

Acquisitions and Discontinued_3

Acquisitions and Discontinued Operations - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Mar. 29, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Acquisition		$ 559	$ 1,249,233
Goodwill		1,638,846	1,636,705	$ 390,185
Goodwill expected tax deductible amount		33,000
Net Income (Loss)		(41,301)	22,389	221,589
Acquisition-related charges		$ 17,500	48,100	3,000
Minimum | Primarily Customer Contracts, A Trade Name And Payor And Capitated Relationships
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Estimated weighted average useful lives	1 year
Maximum | Primarily Customer Contracts, A Trade Name And Payor And Capitated Relationships
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Estimated weighted average useful lives	15 years
Apria Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Acquisition debt			108,000
Apria Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of business acquired	100%
Business combination, consideration transferred	$ 1,700,000
Cash acquired from acquisition	144,000
Fair value receivables	88,700
Goodwill	$ 1,251,347
Pro forma net loss			97,687	$ (286,466)
Pro forma, adjustments for interest expense			20,800
Pro forma, amortization of intangible assets			10,500
Seller transaction and stock compensation expense			39,400
Revenue			937,000
Net Income (Loss)			$ 3,300

Acquisitions and Discontinued_4

Acquisitions and Discontinued Operations - Estimated Fair Value of The Assets Acquired and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Mar. 29, 2022	Dec. 31, 2021
Assets acquired:
Goodwill	$ 1,638,846	$ 1,636,705		$ 390,185
Apria Inc
Assets acquired:
Current assets			$ 139,560
Goodwill			1,251,347
Intangible assets			315,300
Other non-current assets			354,237
Total assets			2,060,444
Liabilities assumed:
Current liabilities			247,276
Noncurrent liabilities			128,561
Total liabilities			375,837
Fair value of net assets acquired, net of cash			$ 1,684,607

Acquisition and Discontinued Op

Acquisition and Discontinued Operations - Pro Forma (Details) - Apria Inc - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Net revenue	$ 10,232,588	$ 10,930,590
Net (loss) income	$ (97,687)	$ 286,466

Merchandise Inventories (Detail

Merchandise Inventories (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2023
Inventory [Line Items]
Merchandise inventories	$ 1,333,585	$ 1,110,606
LIFO inventory amount	840,000	718,000
Current costs or first-in, first-out (FIFO) excess of replacement over stated LIFO value	231,000	233,000
Raw materials	84,400	75,700
Work in process	$ 73,700	61,500
Inventory share basic (in usd per share)	$ 0.93
Inventory share diluted (in usd per share)	$ 0.91
inventory valuation allowances	$ 128,000	$ 78,200
SEC Schedule, 12-09, Reserve, Inventory
Inventory [Line Items]
Change in inventory valuation allowance	92,300
Change in inventory valuation allowance, net of tax	$ 69,600

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,090,369	$ 1,028,555
Accumulated depreciation and amortization	(546,397)	(450,286)
Property and equipment, net	543,972	578,269
Land and land improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	22,959	22,849
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	201,939	197,228
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	492,551	470,071
Patient service equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	362,192	324,007
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 10,728	$ 14,400

Property and Equipment, Net - N

Property and Equipment, Net - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 188	$ 136	$ 40.5

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill impairment charge	$ 0	$ 0	$ 0
Intangible assets, net	361,835	445,042
Intangible amortization	83,500	78,800	$ 39,800
Patient Direct
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	250,000	308,000
Products & Healthcare Services
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$ 112,000	$ 137,000

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Goodwill Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 1,636,705	$ 390,185
Currency translation adjustments	1,582	(2,713)
Acquisition	559	1,249,233
Goodwill, ending balance	1,638,846	1,636,705
Patient Direct
Goodwill [Roll Forward]
Goodwill, beginning balance	1,533,670	283,905
Currency translation adjustments	1,582	0
Acquisition	0	1,249,765
Goodwill, ending balance	1,535,252	1,533,670
Products & Healthcare Services
Goodwill [Roll Forward]
Goodwill, beginning balance	103,035	106,280
Currency translation adjustments	0	(2,713)
Acquisition	559	(532)
Goodwill, ending balance	$ 103,594	$ 103,035

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Net intangible assets	$ 361,835	$ 445,042
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	433,750	447,107
Accumulated amortization	(236,791)	(197,540)
Net intangible assets	$ 196,959	$ 249,567
Weighted average useful life	13 years	13 years
Tradenames
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	$ 202,000	$ 202,000
Accumulated amortization	(69,655)	(50,094)
Net intangible assets	$ 132,345	$ 151,906
Weighted average useful life	10 years	10 years
Other Intangibles
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	$ 73,958	$ 73,181
Accumulated amortization	(41,427)	(29,612)
Net intangible assets	$ 32,531	$ 43,569
Weighted average useful life	6 years	6 years

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, Net - estimated future amortization expense (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Estimated future amortization expense
2024	$ 64,594
2025	54,608
2026	50,255
2027	41,906
2028	32,081
Thereafter	118,391
Total future amortization	$ 361,835

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finance lease cost:
Interest on lease liabilities	$ 1,232	$ 1,516	$ 1,255
Total finance lease cost	3,383	4,271	2,353
Total lease cost	166,754	125,351	80,112
DS&A Expenses
Lessee, Lease, Description [Line Items]
Operating lease cost	109,942	81,520	59,397
Finance lease cost:
Amortization of lease assets	2,151	2,755	1,098
DS&A Expenses, Cost of goods sold
Finance lease cost:
Short-term lease cost	8,271	4,129	871
Variable lease cost	$ 45,158	$ 35,431	$ 17,491

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease assets	$ 296,533	$ 280,665
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property and equipment, net	Property and equipment, net
Finance lease assets	$ 8,477	$ 10,194
Total lease assets	$ 305,010	$ 290,859
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Current operating lease liabilities	$ 85,665	$ 76,805
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Current finance lease liabilities	$ 2,822	$ 2,531
Noncurrent operating lease liabilities	$ 222,429	$ 215,469
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt, excluding current portion	Long-term debt, excluding current portion
Noncurrent finance lease liabilities	$ 9,557	$ 11,877
Present value of lease liabilities	$ 320,473	$ 306,682

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Finance leases, gross	$ 22,200	$ 21,500
Finance leases, accumulated depreciation	13,700	11,300
Operating lease assets	$ 296,533	$ 280,665

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating and finance leases	$ 109,726	$ 81,821	$ 59,192
Financing cash flows from finance leases	2,523	2,850	1,199
Right-of-use assets obtained in exchange for new operating and finance lease liabilities	$ 116,230	$ 75,188	$ 96,988
Weighted average remaining lease term (years)
Operating leases	3 years 10 months 24 days	4 years 3 months 18 days	4 years 10 months 24 days
Finance leases	4 years 3 months 18 days	5 years 2 months 12 days	6 years 4 months 24 days
Weighted average discount rate
Operating leases	7.30%	6.90%	8.80%
Finance leases	10.30%	9.90%	10.80%

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating Leases
2024	$ 112,868
2025	92,510
2026	70,946
2027	46,597
2028	28,720
Thereafter	17,650
Total lease payments	369,291
Less: Interest	(61,197)
Present value of lease liabilities	308,094
Finance Leases
2024	3,753
2025	3,657
2026	2,758
2027	2,302
2028	2,033
Thereafter	511
Total lease payments	15,014
Less: Interest	(2,635)
Present value of lease liabilities	12,379
Total
2023	116,621
2024	96,167
2025	73,704
2026	48,899
2027	30,753
Thereafter	18,161
Total lease payments	384,305
Less: Interest	(63,832)
Present value of lease liabilities	$ 320,473	$ 306,682

Exit and Realignment Costs - Ex

Exit and Realignment Costs - Exit and realignment charges by segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Exit and realignment charges	$ 99,127	$ 6,897	$ 31,109
Operating Model Realignment Program And I T
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 92,200

Exit and Realignment Costs - Ac

Exit and Realignment Costs - Accrual for Exit and Realignment Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Reserve [Roll Forward]
Accrued exit and realignment charges, beginning balance	$ 969	$ 8,306	$ 3,146
Cash payments	(76,643)	(13,502)	(14,787)
Accrued exit and realignment charges, ending balance	20,047	969	8,306
Severance
Restructuring Reserve [Roll Forward]
Restructuring charges	11,556	2,018	9,191
Information system restructuring costs
Restructuring Reserve [Roll Forward]
Restructuring charges			4,752
Lease obligations
Restructuring Reserve [Roll Forward]
Restructuring charges			440
Professional fees
Restructuring Reserve [Roll Forward]
Restructuring charges	63,699
Vendor contract and lease termination costs
Restructuring Reserve [Roll Forward]
Restructuring charges	6,198
IT strategic initiatives
Restructuring Reserve [Roll Forward]
Restructuring charges	8,649
Other
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 5,619	$ 4,147	$ 5,564

Exit and Realignment Costs - Na

Exit and Realignment Costs - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Incurred cost		$ 700
RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag	costs that were expensed as incurred
Provision for losses on accounts receivable	$ (1,414)	$ 3,315	$ 21,158
Fusion5
Restructuring Cost and Reserve [Line Items]
Incurred cost	$ 3,400		$ 11,200

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Mar. 29, 2022	Mar. 10, 2021
Debt Instrument [Line Items]
Finance leases and other	$ 12,379
Long-term debt	$ 1,890,598	$ 2,482,968
Senior Notes | 4.375% Senior Notes, due December 2024
Debt Instrument [Line Items]
Interest rate of debt	4.375%
Senior Notes | 4.500% Senior Notes, due March 2029
Debt Instrument [Line Items]
Interest rate of debt	4.50%			4.50%
Senior Notes | 6.625% Senior Notes, due April 2030
Debt Instrument [Line Items]
Interest rate of debt	6.625%		6.625%
Carrying Amount
Debt Instrument [Line Items]
Total debt	$ 2,097,502	2,500,874
Less current maturities	(206,904)	(17,906)
Long-term debt	1,890,598	2,482,968
Carrying Amount | Finance leases and other
Debt Instrument [Line Items]
Finance leases and other	22,153	16,877
Carrying Amount | Senior Notes | 4.375% Senior Notes, due December 2024
Debt Instrument [Line Items]
Long-term debt	171,232	245,510
Carrying Amount | Senior Notes | 4.500% Senior Notes, due March 2029
Debt Instrument [Line Items]
Long-term debt	472,869	492,762
Carrying Amount | Senior Notes | 6.625% Senior Notes, due April 2030
Debt Instrument [Line Items]
Long-term debt	540,445	585,180
Carrying Amount | Receivables Securitization Program
Debt Instrument [Line Items]
Long-term debt	0	93,142
Carrying Amount | Secured Debt | Term Loan A
Debt Instrument [Line Items]
Long-term debt	387,591	490,816
Carrying Amount | Secured Debt | Term Loan B
Debt Instrument [Line Items]
Long-term debt	503,212	576,587
Estimated Fair Value
Debt Instrument [Line Items]
Total debt	2,051,987	2,346,067
Less current maturities	(206,904)	(17,906)
Long-term debt	1,845,083	2,328,161
Estimated Fair Value | Finance leases and other
Debt Instrument [Line Items]
Finance leases and other	22,153	16,877
Estimated Fair Value | Senior Notes | 4.375% Senior Notes, due December 2024
Debt Instrument [Line Items]
Long-term debt	168,754	237,772
Estimated Fair Value | Senior Notes | 4.500% Senior Notes, due March 2029
Debt Instrument [Line Items]
Long-term debt	422,647	396,625
Estimated Fair Value | Senior Notes | 6.625% Senior Notes, due April 2030
Debt Instrument [Line Items]
Long-term debt	529,472	516,060
Estimated Fair Value | Receivables Securitization Program
Debt Instrument [Line Items]
Long-term debt	0	96,000
Estimated Fair Value | Secured Debt | Term Loan A
Debt Instrument [Line Items]
Long-term debt	390,668	485,000
Estimated Fair Value | Secured Debt | Term Loan B
Debt Instrument [Line Items]
Long-term debt	$ 518,293	$ 597,733

Debt - Narrative (Details)

Debt - Narrative (Details) $ in Thousands			12 Months Ended
	Mar. 29, 2022 USD ($) item	Mar. 10, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Number of credit facilities | item	2
2024			$ 199,197
Short-term finance leases			2,822	$ 2,531
Short-term finance lease and other			7,700
Term Loan B
Debt Instrument [Line Items]
Face amount	$ 450,000
Maximum borrowing capacity	150,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding, amount			3,000	2,300
Line of Credit
Debt Instrument [Line Items]
Line of credit facility, remaining borrowing capacity			423,000	422,000
2024			199,000
Line of Credit | Payments due in December related to the 2024 Notes, Term Loan A, and Term Loan B
Debt Instrument [Line Items]
2024			179,000
Long-term debt, maturity, principal payments			171,000
Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding, amount			27,400	27,900
4.375% Senior Notes, due December 2024 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, cash to repurchase amount			73,500
Face amount			$ 74,700
Interest rate of debt			4.375%
Debt issued, percent of par			99.60%
Effective yield percentage			4.422%
Senior notes redemption price, percentage			100%
Rate of interest discounted			0.30%
4.375% Senior Notes, due December 2024 | Senior Notes | Carrying Amount
Debt Instrument [Line Items]
Long-term debt			$ 171,232	245,510
Receivables Financing Agreement
Debt Instrument [Line Items]
Current borrowing capacity	450,000
Borrowings outstanding			0
Letters of credit outstanding, amount				96,000
Receivables Financing Agreement | Line of Credit
Debt Instrument [Line Items]
Line of credit facility, remaining borrowing capacity			450,000	354,000
Term Loan A
Debt Instrument [Line Items]
Face amount	500,000
Scheduled principal payment			9,400
Unscheduled principal payment			97,500
Long-term debt, maturity, principal payments			21,900
Term Loan B
Debt Instrument [Line Items]
Face amount	600,000
Scheduled principal payment			6,000
Unscheduled principal payment			72,500
Long-term debt, maturity, principal payments			6,000
4.500% Senior Notes, due March 2029 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, cash to repurchase amount			18,200
Face amount		$ 500,000	$ 21,300
Interest rate of debt		4.50%	4.50%
Debt issued, percent of par		100%
Effective yield percentage		4.50%
Senior notes redemption price, percentage			100%
4.500% Senior Notes, due March 2029 | Senior Notes | Carrying Amount
Debt Instrument [Line Items]
Long-term debt			$ 472,869	492,762
4.500% Senior Notes, due March 2029 | Senior Notes | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Senior notes redemption price, percentage			104.50%
Redemption price, percentage of principal amount redeemed			40%
6.625% Senior Notes, due April 2030 | Senior Notes
Debt Instrument [Line Items]
Debt instrument, cash to repurchase amount			$ 43,500
Face amount	$ 600,000		$ 47,800
Interest rate of debt	6.625%		6.625%
Debt issued, percent of par	100%
Effective yield percentage	6.625%
Senior notes redemption price, percentage			100%
6.625% Senior Notes, due April 2030 | Senior Notes | Carrying Amount
Debt Instrument [Line Items]
Long-term debt			$ 540,445	$ 585,180
6.625% Senior Notes, due April 2030 | Senior Notes | Payments due in December related to the 2024 Notes, Term Loan A, and Term Loan B
Debt Instrument [Line Items]
Redemption price, percentage of principal amount redeemed			40%
6.625% Senior Notes, due April 2030 | Senior Notes | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Senior notes redemption price, percentage			106.625%

Debt - Schedule of Future Princ

Debt - Schedule of Future Principal Payments of Debt (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Debt Disclosure [Abstract]
2024	$ 199,197
2025	40,375
2026	43,500
2027	305,375
2028	6,000
2029	965,654
2030	$ 552,189

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for issuance under share-based compensation plan (shares)	3.6
Total share-based compensation expense	$ 23.2	$ 21	$ 25
Recognized tax benefits from share-based compensation expense	$ 6	5.5	6.5
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	3 years
Total unrecognized compensation cost related to nonvested awards	$ 28.4
Total unrecognized compensation cost related to nonvested awards, period for recognition	2 years
Restricted Stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	1 year
Restricted Stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	5 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	3 years
Total unrecognized compensation cost related to nonvested awards	$ 0.9
RSAs and PSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of stock that vested during the period	$ 24.4	$ 21.6	$ 16.8

Share-Based Compensation - Acti

Share-Based Compensation - Activity and Value of Nonvested RSAs and PSAs (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Number of Shares
Nonvested awards at beginning of year (shares)	2,777	4,325	4,816
Granted (shares)	3,137	2,745	2,758
Vested (shares)	(1,736)	(2,667)	(1,801)
Forfeited (shares)	(977)	(1,626)	(1,448)
Nonvested awards at end of year (shares)	3,201	2,777	4,325
Weighted Average Grant-date Fair Value Per Share
Nonvested awards at beginning of year (dollars per share)	$ 22.52	$ 11.57	$ 7.64
Granted (dollars per share)	18.34	19.10	14.10
Vested (dollars per share)	14.04	8.11	9.33
Forfeited (dollars per share)	26.82	11.25	6.10
Nonvested awards at end of year (dollars per share)	$ 21.70	$ 22.52	$ 11.57

Retirement Plans - Narrative (D

Retirement Plans - Narrative (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
United States
Defined Benefit Plan Disclosure [Line Items]
Expected net actuarial loss	$ 200
Accumulated benefit obligation	34,059	$ 39,341
Net periodic benefit cost	2,258	2,099	$ 2,279
Foreign Plan
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	15,500	11,800
Net periodic benefit cost	4,300	3,600	3,600
Savings And Retirement Plans
Defined Benefit Plan Disclosure [Line Items]
Expense recognized	$ 15,000	$ 14,000	$ 23,200

Retirement Plans - Domestic Ret

Retirement Plans - Domestic Retirement Plan's Financial Status and Amounts Recognized in Consolidated Balance Sheets (Detail) - United States - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Change in benefit obligation
Benefit obligation, beginning of year	$ 39,341	$ 50,244
Interest cost	1,827	1,176	$ 1,080
Actuarial gain	(3,787)	(8,359)
Benefits paid	(3,322)	(3,720)
Benefit obligation, end of year	34,059	39,341	50,244
Change in plan assets
Fair value of plan assets, beginning of year	0	0
Employer contribution	3,322	3,720
Benefits paid	(3,322)	(3,720)
Fair value of plan assets, end of year	0	0	$ 0
Funded status, end of year	(34,059)	(39,341)
Amounts recognized in the consolidated balance sheets
Other current liabilities	(2,975)	(3,604)
Other liabilities	(31,084)	(35,737)
Accumulated other comprehensive loss	6,331	10,550
Net amount recognized	(27,728)	(28,791)
Accumulated benefit obligation	$ 34,059	$ 39,341
Weighted average assumptions used to determine benefit obligation
Discount rate	4.68%	4.87%

Retirement Plans - Components o

Retirement Plans - Components of Net Periodic Benefit Cost for Domestic Retirement Plans (Detail) - United States - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Interest cost	$ 1,827	$ 1,176	$ 1,080
Recognized net actuarial loss	431	923	1,199
Net periodic benefit cost	$ 2,258	$ 2,099	$ 2,279
Discount rate	4.87%	2.43%	1.95%

Retirement Plans - Amounts Reco

Retirement Plans - Amounts Recognized As Component Of Accumulated Other Comprehensive Loss, Domestic (Detail) - United States - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Net actuarial loss	$ (6,331)	$ (10,550)
Deferred tax benefit	3,867	4,964
Amounts included in accumulated other comprehensive loss, net of tax	$ (2,464)	$ (5,586)

Retirement Plans - Expected Ben

Retirement Plans - Expected Benefit Payments Required For Domestic Retirement Plan (Detail) - United States $ in Thousands	Dec. 31, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
2023	$ 2,942
2024	2,790
2025	2,627
2026	2,479
2027	2,333
2028-2032	$ 9,234

Derivatives - Summary of the te

Derivatives - Summary of the terms and fair value of our outstanding derivative financial instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Economic (non-designated) hedges | Foreign currency contracts
Derivative [Line Items]
Notional Amount	$ 78,436	$ 58,321
Cash flow hedges | Interest rate swaps
Derivative [Line Items]
Notional Amount	350,000	400,000
Other assets, net | Cash flow hedges | Interest rate swaps
Derivative [Line Items]
Derivative Asset, Fair Value	8,447	15,461
Other current assets | Economic (non-designated) hedges | Foreign currency contracts
Derivative [Line Items]
Derivative Asset, Fair Value	1,043	440
Other liabilities | Cash flow hedges | Interest rate swaps
Derivative [Line Items]
Derivative Liabilities, Fair Value	0
Other current liabilities | Economic (non-designated) hedges | Foreign currency contracts
Derivative [Line Items]
Derivative Liabilities, Fair Value	$ 0	$ 42

Derivatives - Narrative (Detail

Derivatives - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Derivative [Line Items]
Notional amount	$ 50
Designated as Hedging Instrument | Interest rate swaps
Derivative [Line Items]
Derivative, terminated notional value				$ 300
Designated as Hedging Instrument | Interest expense, net | Interest rate swaps
Derivative [Line Items]
Derivative, terminated notional value			$ 25.1
Economic (non-designated) hedges | Foreign currency contracts
Derivative [Line Items]
Loss on derivative not designed as hedging instrument	$ 0.3	$ 0.9	$ 2.3

Derivatives - Summary of the ef

Derivatives - Summary of the effect of cash flow hedge (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded	$ (157,915)	$ (128,891)	$ (48,090)
Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Recognized in Other Comprehensive Income (Loss)	2,707	14,814	2,426
Interest expense, net | Interest rate swaps | Reclassification out of Accumulated Other Comprehensive Income
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Income	$ 9,720	(647)	(25,518)
Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded		$ (128,891)	$ (40,433)

Income Taxes - Components of In

Income Taxes - Components of Income (Loss) before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income from continuing operations before income taxes:
U.S.	$ (65,432)	$ (17,650)	$ 231,424
Foreign	10,706	28,541	45,330
(Loss) income before income taxes	$ (54,726)	$ 10,891	$ 276,754

Income Taxes - Income Tax Provi

Income Taxes - Income Tax Provision (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current tax provision (benefit):
Federal	$ 3,887	$ 1,090	$ 54,087
State	1,535	5,125	15,961
Foreign	4,886	8,648	14,853
Total current tax provision	10,308	14,863	84,901
Deferred tax provision (benefit):
Federal	(18,081)	(8,671)	(22,046)
State	(4,823)	(5,395)	(4,175)
Foreign	(829)	(12,295)	(3,515)
Total deferred tax provision (benefit)	(23,733)	(26,361)	(29,736)
Total income tax (benefit) provision	$ (13,425)	$ (11,498)	$ 55,165

Income Taxes - Reconciliation O

Income Taxes - Reconciliation Of Federal Statutory Rate To Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal statutory rate	21%	21%	21%
Increases (decreases) in the rate resulting from:
Net capital loss on divestiture	0	0	(0.010)
Tax reform	0%	0%	(1.20%)
Unrecognized tax benefits	(2.60%)	10.20%	0.10%
State income taxes, net of federal income tax impact	6.40%	(7.10%)	3.10%
Research and development credit	4.40%	(29.90%)	(0.80%)
Foreign income taxes	(0.90%)	0.50%	0.30%
Valuation allowance	(0.50%)	0%	1.10%
Restricted stock vestings	(1.00%)	(57.30%)	(2.10%)
Nondeductible Interest	(1.50%)	6.60%	0.30%
Nondeductible compensation	(3.60%)	28.90%	1%
Foreign repatriation change (Thailand)	0%	(96.30%)	0%
Non-deductible transaction costs	0%	19.50%	0%
Foreign derived intangible income (FDII)	4%	0%	(3.20%)
Global intangible low-taxed income	0.70%	5%	0%
Other	(1.90%)	(6.70%)	1.30%
Effective income tax rate	24.50%	(105.60%)	19.90%

Income Taxes - Tax Effects On D

Income Taxes - Tax Effects On Deferred Tax Assets And Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Employee benefit plans	$ 28,763	$ 27,923
Accrued liabilities not currently deductible	15,997	15,640
Finance charges	2,173	2,143
Lease liabilities	83,895	80,300
Allowance for losses on accounts receivable	7,335	6,703
Net operating loss carryforwards	41,165	55,992
Capital loss carryover	30,034	30,034
Interest limitation	13,082	19,890
Insurance	1,323	20
R&D Capitalized Costs	21,974	14,017
Other	8,462	7,982
Total deferred tax assets	254,203	260,644
Less: valuation allowances	(35,520)	(35,253)
Net deferred tax assets	218,683	225,391
Deferred tax liabilities:
Merchandise inventories	25,866	18,904
Goodwill	5,426	4,151
Property and equipment	69,411	91,983
Right-of-use assets	79,303	75,623
Derivatives	2,196	4,020
Intangible assets	62,301	81,068
Other	859	826
Total deferred tax liabilities	245,362	276,575
Net deferred tax liability	$ (26,679)	$ (51,184)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 116,000,000
Cash payments for income taxes, including interest	13,400,000	$ 38,100,000	$ 102,000,000
Proceeds from income tax refunds	19,700,000	4,200,000	2,500,000
Decrease in unrecognized tax benefits is reasonably possible	2,700,000	2,700,000
Unrecognized tax benefits that would impact effective tax rate	20,000,000	19,800,000
Accrued interest	5,700,000	3,900,000
Interest on income tax expense	1,700,000	1,000,000	300,000
Penalties accrued	$ 0	$ 0	$ 0

Income Taxes - Reconciliation_2

Income Taxes - Reconciliation Of Changes In Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits at January 1,	$ 22,499	$ 21,385
Increases for positions taken during current period	410	1,016
Increases for positions taken during prior periods	13	325
Lapse of statute of limitations	(181)	(227)
Unrecognized tax benefits at December 31,	$ 22,741	$ 22,499

Net Income per Common Share - S

Net Income per Common Share - Summary of Calculation of Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Income (Loss)	$ (41,301)	$ 22,389	$ 221,589
Weighted average number of shares outstanding, basic (in shares)	75,785	74,496	72,744
Dilutive shares (in shares)	0	1,721	2,742
Weighted average number of shares outstanding, diluted (in shares)	75,785	76,217	75,486
Basic income (loss) per common share:
Income from continuing operations (in usd per share)	$ (0.54)	$ 0.30	$ 3.05
Net income	(0.54)	0.30	3.05
Diluted income (loss) per common share:
Income from continuing operations (in usd per share)	(0.54)	0.29	2.94
Net income	$ (0.54)	$ 0.29	$ 2.94
Shares excluded from calculation of net loss Per diluted common share	1,600

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	$ 945,604	$ 938,501	$ 712,054
Total other comprehensive income (loss), net of tax	4,037	4,736	(2,082)
Ending balance	924,166	945,604	938,501
Retirement Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(7,201)	(14,597)	(18,447)
Other comprehensive income (loss) before reclassifications	2,405	8,359	4,462
Income tax	(639)	(1,646)	(1,428)
Other comprehensive income (loss) before reclassifications, net of tax	1,766	6,713	3,034
Amounts reclassified from accumulated other comprehensive loss	431	923	1,199
Income tax	(111)	(240)	(383)
Amounts reclassified from accumulated other comprehensive loss, net of tax	320	683	816
Total other comprehensive income (loss), net of tax	2,086	7,396	3,850
Ending balance	(5,115)	(7,201)	(14,597)
Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(40,095)	(25,994)	(18)
Other comprehensive income (loss) before reclassifications	7,141	(14,101)	(25,976)
Income tax	0	0	0
Other comprehensive income (loss) before reclassifications, net of tax	7,141	(14,101)	(25,976)
Amounts reclassified from accumulated other comprehensive loss	0	0	0
Income tax	0	0	0
Amounts reclassified from accumulated other comprehensive loss, net of tax	0	0	0
Total other comprehensive income (loss), net of tax	7,141	(14,101)	(25,976)
Ending balance	(32,954)	(40,095)	(25,994)
Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	11,441	0	(20,044)
Other comprehensive income (loss) before reclassifications	2,707	14,814	2,426
Income tax	(704)	(3,851)	(611)
Other comprehensive income (loss) before reclassifications, net of tax	2,003	10,963	1,815
Amounts reclassified from accumulated other comprehensive loss	(9,720)	647	25,518
Income tax	2,527	(169)	(7,289)
Amounts reclassified from accumulated other comprehensive loss, net of tax	(7,193)	478	18,229
Total other comprehensive income (loss), net of tax	(5,190)	11,441	20,044
Ending balance	6,251	11,441	0
Total
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(35,855)	(40,591)	(38,509)
Other comprehensive income (loss) before reclassifications	12,253	9,072	(19,088)
Income tax	(1,343)	(5,497)	(2,039)
Other comprehensive income (loss) before reclassifications, net of tax	10,910	3,575	(21,127)
Amounts reclassified from accumulated other comprehensive loss	(9,289)	1,570	26,717
Income tax	2,416	(409)	(7,672)
Amounts reclassified from accumulated other comprehensive loss, net of tax	(6,873)	1,161	19,045
Total other comprehensive income (loss), net of tax	4,037	4,736	(2,082)
Ending balance	$ (31,818)	$ (35,855)	$ (40,591)

Segment Information - Financial

Segment Information - Financial Information by Segment (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) segment	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	2
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue	$ 10,333,967	$ 9,955,475	$ 9,785,315
Operating earnings (loss)	104,508	142,913	368,473
Intangible amortization	(83,500)	(78,800)	(39,800)
Acquisition-related charges and intangible amortization	101,037	126,972	42,774
Exit and realignment charges	(99,127)	(6,897)	(31,109)
Inventory valuation adjustment	0	(92,275)	0
Depreciation and amortization	287,377	228,667	90,621
Consolidated share-based compensation	23,218	20,993	25,016
Consolidated capital expenditures	207,892	166,582	49,690
Operating Segments
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue	10,333,967	9,955,475	9,785,315
Operating Segments | Products & Healthcare Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue	7,781,395	7,898,397	8,825,646
Operating earnings (loss)	57,809	175,309	384,390
Depreciation and amortization	77,006	77,539	75,548
Consolidated share-based compensation	15,078	19,681	22,476
Consolidated capital expenditures	29,361	49,824	48,282
Operating Segments | Patient Direct
Segment Reporting, Revenue Reconciling Item [Line Items]
Net revenue	2,552,572	2,057,078	959,669
Operating earnings (loss)	246,863	193,748	57,966
Depreciation and amortization	210,371	151,128	15,073
Consolidated share-based compensation	5,864	820	937
Consolidated capital expenditures	178,531	116,758	1,408
Segment Reconciling Items
Segment Reporting, Revenue Reconciling Item [Line Items]
Acquisition-related charges and intangible amortization	101,037	126,972	42,774
Consolidated share-based compensation	$ 2,276	$ 492	$ 1,603

Segment Information - Consolida

Segment Information - Consolidated Total Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 5,093,322	$ 5,386,283
Cash and cash equivalents	243,037	69,467
Operating Segments
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	4,850,285	5,316,816
Operating Segments | Products & Healthcare Services
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	2,359,825	2,809,600
Operating Segments | Patient Direct
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 2,490,460	$ 2,507,216

Segment Information - Financi_2

Segment Information - Financial Information by Geographical Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	$ 10,333,967	$ 9,955,475	$ 9,785,315
Long-Lived Assets	1,249,807	1,342,632
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	10,058,675	9,526,037	9,250,331
Long-Lived Assets	1,140,303	1,226,108
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenue	275,292	429,438	$ 534,984
Long-Lived Assets	$ 109,504	$ 116,524

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pay vs Performance Disclosure
Net Income (Loss)	$ (41,301)	$ 22,389	$ 221,589

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false